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Numerous epidemiological studies in diverse populations have demonstrated a link
between low birth weight and a number of cardiovascular risk factors. This
association has given rise to the 'fetal programming hypothesis', which proposes that
a stimulus or insult acting during critical periods of growth and development may
permanently alter tissue structure and function, leading to later disease.
There is increasing evidence that this phenomenon may not be limited to the first
generation offspring; both human and animal studies have demonstrated
intergenerational effects on birth weight and cardiovascular risk; however the
mechanisms behind this remain unclear.
One proposed mechanism to explain the early life origins of disease is fetal
overexposure to glucocorticoids. We have explored the intergenerational effects in
the dexamethasone-programmed rat, a model of fetal programming in which in utero
exposure to excess glucocorticoid results in low birth weight offspring, which
develop glucose intolerance in adulthood, thought to be secondary to an increase in
the activity of a key gluconeogenic enzyme, phosphoenolpyruvate carboxykinase
(PEPCK). Using this model we have demonstrated programming effects in a second
generation of animals, which also showed reduced birth weight, elevated PEPCK and
glucose intolerance; effects which had resolved by the third generation. Although the
persistence of such programming effects in subsequent generations may be
secondary to programmed alterations in maternal physiology, resulting in an adverse
environment for the developing fetus, we also demonstrate a clear effect of paternal
phenotype on offspring birth weight and PEPCK, suggesting that the father also has
an effect on the intergenerational transfer of disease risk.
The association between low birth weight and later disease is amplified by the
development of obesity in humans and in animal models ofmaternal undernutrition.
We have developed a model of high fat feeding in Wistar rats and used this to
explore the effect of obesity in the dexamethasone-programmed rat. After 20 weeks
on a high fat diet, there were no differences in body weight and insulin resistance
between rats exposed to dexamethasone in utero and control animals; however there
was a marked increase in hepatic triglyceride content in the programmed group.
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Thus, the amplification of the programming effect by obesity may be related to
changes in hepatic metabolism and insulin resistance, which may be glucocorticoid
dependent.
These observations demonstrate intergenerational effects of fetal programming by
glucocorticoids, which cannot be explained entirely by the exposure of the fetus to a
programmed adverse maternal environment and indicate the potential importance of
epigenetic factors in the intergenerational inheritance of the 'programming effect'.
In addition we have discovered a potential mechanistic link by which the postnatal
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Chapter One - Introduction
Many epidemiological studies in distinct populations in the UK and the rest of the
world have demonstrated an association between low birth weight and the
subsequent development of hypertension, insulin resistance, type 2 diabetes and
cardiovascular disease (Barker 1998). 'Fetal programming' has been proposed as the
mechanism underlying this association between low birth weight, childhood growth
and subsequent disease. The fetal programming hypothesis proposes that a stimulus
or insult acting during critical periods of growth and development may permanently
alter tissue structure and function. Indeed, evidence from both human and animal
studies (Langley-Evans et al 1996c, Barker 1998, Nyirenda et al 1998, Doyle et al
2000) suggests that many diseases of adult life can be induced by manipulating the
environment of the fetus. There is also evidence that this phenomenon may not be
confined to the first generation; intergenerational effects on birth weight, blood
pressure and glucose tolerance have been reported in both human and animal studies
(Stewart et al 1975, Alcolado & Alcolado 1991, Emanuel et al 1992, Davey Smith et
al 1997, Hoet & Hanson 1999), although the mechanisms remain unclear. We and
others have provided evidence that programming effects may be mediated by
glucocorticoids (Benediktsson et al 1993, Nyirenda et al 1998, Gatford et al 2000,
Newnham 2001, Sloboda et al 2002b) and have developed an animal model of
glucocorticoid programming (Benediktsson et al 1993). The first half of this thesis
explores the intergenerational effects of programming in this model, the
dexamethasone-programmed rat.
Glucocorticoid secretion and metabolism is altered in obesity in humans and animal
models (Andrew et al 1998, Livingstone et al 2000a, Rask et al 2001, Pasquali et al
2002, Lindsay et al 2003, Wake et al 2003). Obesity appears to be important in
modifying the risk of later disease associated with low birth weight (Phillips et al
1994) and amplifies programming effects in some animal models (Vickers et al
2000). In the dexamethasone-programmed rat, local alterations in glucocorticoid
signalling may mediate the observed metabolic changes (Nyirenda et al 1998,
Cleasby et al 2003a); the programmed animal may therefore be more susceptible to
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obesity and its sequelae. The second half of this thesis explores the amplification of
the programming phenotype by obesity.
This introductory chapter reviews the evidence and potential mechanisms for fetal
programming and for intergenerational effects in human and animal models. The role
of obesity in the amplification of programming is also discussed. Glucocorticoid
physiology and metabolism is reviewed, with particular emphasis on the role of
glucocorticoids in obesity. Finally, the aims of this thesis are listed.
1.1 Background
The association between low birth weight and later disease has now been described
in many populations (Barker 1998) and appears to be independent of classical
lifestyle risk factors such as smoking, adult weight, social class, alcohol and lack of
exercise, which are additive to the effect (Barker et al 1993a). Importantly, the
association holds for the full range of birth weights, including those within the
normal range. In addition, a number of studies have suggested that faster post-natal
catch-up growth may also be predictive of later risk of cardiovascular disease
(Barker et al 1993a, Bavdekar et al 1999, Eriksson et al 1999, Forsen et al 2000, Law
et al 2002).
The relative importance of genetic and environmental factors in this phenomenon
remains unknown. Two major environmental hypotheses have been proposed to
explain the mechanism by which low birth weight is associated with adult disease:
fetal undernutrition (Barker & Osmond 1986); and overexposure of the fetus to
glucocorticoids (Edwards et al 1993). A third hypothesis suggests that genetic factors
may lead to both low birth weight and subsequent risk of cardiovascular disease;
indeed, genetic loci have recently been described which may link smallness at birth
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Figure 1.1 Potential mechanisms for fetal programming.
Two major environmental hypotheses have been proposed to explain the mechanism
by which low birth weight is associated with adult disease: fetal undernutrition; and
overexposure of the fetus to glucocorticoids. A third hypothesis suggests that genetic
factors may lead to both low birth weight and subsequent risk of cardiovascular
disease, for example a genetically mediated insulin resistance may lead to both





Many reports have now described links between low birth weight, fetal environment
and the risk of later disease in humans (Barker 2002). Epidemiological studies have
demonstrated associations between fetal and infant growth and the risk of developing
impaired glucose tolerance, type 2 diabetes, coronary heart disease, hypertension and
hyperlipidaemia; a cluster of factors known as the metabolic syndrome (reviewed in
Barker 1998, Barker 2002).
1.2.1 Cardiovascular disease
Initial clues that fetal development may be associated with later disease came from
epidemiological studies demonstrating that death rates from cardiovascular disease
were highest in areas of the UK that had the highest infant mortality during the early
20th century (Barker & Osmond 1986). The Hertfordshire cohort comprised 16,000
men and women born in Hertfordshire between 1911 and 1930, and in these
individuals, death rates from coronary heart disease decreased with increasing birth
weight (Osmond et al 1993). Similar findings have been reported from other cohorts
in the UK (Barker et al 1993c) and elsewhere in the world (Rich-Edwards et al 1997,
Forsen et al 1999, Eriksson et al 2000). Many studies have also shown an association
between low birth weight and hypertension (reviewed in Barker 1998).
1.2.2 Type 2 diabetes
Studies in the Hertfordshire and Preston cohorts have shown that low birth weight
and thinness at birth is associated with insulin resistance (Barker et al 1993b, Phipps
et al 1993, Phillips et al 1994). These observations have been confinned in Sweden
(Lithell et al 1996), Finland (Forsen et al 2000, Eriksson et al 2002) and the US
(Rich-Edwards et al 1999).
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1.2.3 The hypothalamic-pituitary adrenal (HPA) axis
Low birth weight is also associated with long-term effects on the HPA axis (Phillips
et al 1998, Phillips et al 2000). Individuals with lower birth weight have evidence of
chronic activation of the HPA axis (Levitt et al 2000, Reynolds et al 2001). As
increased Cortisol concentrations in blood, saliva and urine are associated with
features of the metabolic syndrome (Phillips et al 1998, Phillips et al 2000),
programming of the HPA axis may underlie the association between low birth weight
and later disease.
1.2.4 Animal models of fetal programming
Potential mechanisms underlying fetal programming have been explored using a
number of animal models. Both maternal undernutrition (low protein or low calorie
diets during gestation) and in utero overexposure to glucocorticoids results in
offspring of lower birth weight which subsequently develop glucose intolerance,
hypertension and HPA axis activation (reviewed in Ozanne 2001). These models will
be discussed in more detail below.
1.3 Potential mechanisms for fetal programming
1.3.1 Glucocorticoid programming
Steroid hormones are typically associated with long-term organisational effects and
are therefore prime candidates to explain programming. For example, neonatal
exposure to androgens permanently programmes the expression of hepatic steroid
metabolising enzymes and the development of sexually dimorphic structures in the
anterior hypothalamus as well as sexual behaviour (Arai & Gorski 1968, Gustafsson
et al 1983). These effects can only be exerted during a specific perinatal period, and
the mechanisms may reflect the influence of androgens on organ growth and
maturation. In the rat, the sexually dimorphic nucleus of the hypothalamic preoptic
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area is larger in males. Testosterone inhibits apoptosis specifically between postnatal
days 6 and 10 in this nucleus, producing the male phenotype (Davis et al 1996).
Fetal glucocorticoid overexposure has been proposed as a mechanism underpinning
the early life programming of adult disease. Glucocorticoid receptors (GR) are
expressed in most fetal tissues from early in gestation (Cole et al 1995) and are also
expressed in the placenta (Sun et al 1997). The higher affinity mineralocorticoid
receptor (MR) is also expressed in fetal tissues, but has a more limited tissue
distribution and is present at a later gestational stage (Brown et al 1996b). Perinatal
glucocorticoids alter the rate ofmaturation of various organs, such as the lung (Ward
1994), heart (Bian et al 1992, Bian et al 1993) and kidney (Celsi et al 1997) and are
used therapeutically in threatened preterm labour for this reason. In addition to the
widespread use of glucocorticoids to enhance fetal lung maturation in the
management ofwomen at risk ofpreterm delivery, they are also used in the antenatal
management of fetuses at risk of congenital adrenal hyperplasia.
Glucocorticoid treatment during pregnancy reduces birth weight in animals including
non-human primates (Reinisch et al 1978, Ikegami et al 1997, Nyirenda et al 1998,
Newnham et al 1999, Newnham & Moss 2001). Human studies have confirmed that
antenatal glucocorticoids are associated with a reduction in birth weight (French et al
1999, Bloom et al 2001), although normal birth weight has been reported in infants at
risk of congenital adrenal hyperplasia receiving low dose dexamethasone in utero
from the first trimester (Forest et al 1993, Mercado et al 1995). Fetal Cortisol levels
are increased in human fetuses with intrauterine growth retardation or in pregnancies
complicated by pre-eclampsia, which may indicate a role for endogenous Cortisol in
fetal growth retardation (Goland et al 1993, Goland et al 1995). Cortisol also affects
placental size, the effect dependent on the dose and the timing of exposure (Gunberg
1957).
Many glucocorticoid sensitive systems are affected by early-life programming.
Glucocorticoids are essential for normal brain development, exerting a number of
effects in most regions of the developing brain including the hippocampus and the
hypothalamic-pituitary-adrenal (HPA) axis and perinatal glucocorticoids have been
shown to programme specific effects in the brain (Welberg & Seckl 2001).
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Glucocorticoids are known to increase blood pressure in adults. Cortisol elevates the
blood pressure in fetal sheep when infused directly in utero (Tangalakis et al 1992)
and at birth in humans (Kari et al 1994) and in sheep (Berry et al 1997). The
administration of betamethasone to pregnant baboons elevates fetal blood pressure
(Koenen et al 2002). Antenatal glucocorticoid exposure also leads to permanently
elevated blood pressure in later life. Rats treated with dexamethasone in utero have
elevated blood pressure in adulthood (Benediktsson et al 1993, Sugden et al 2001), as
do sheep exposed to excess glucocorticoid in utero either as maternally-administered
dexamethasone or as a maternal Cortisol infusion (Dodic et al 2001, Dodic et al
2002a, Dodic et al 2002b, Jensen et al 2002). The timing of glucocorticoid exposure
appears to be important; exposure to glucocorticoids during the final week of
pregnancy is sufficient to produce permanent adult hypertension in the rat (Levitt et
al 1996), whereas in sheep, such effects are seen after glucocorticoid exposure earlier
in gestation (Gatford et al 2000).
Maternal glucocorticoid administration has an effect on cord glucose and insulin
levels in the ovine fetus (Sloboda et al 2002b) and on glucose homeostasis in the
adult offspring. Intriguingly, in sheep, antenatal glucocorticoid exposure with or
without fetal growth restriction altered glucose metabolism (Moss et al 2001).
Maternal but not fetal injections of betamethasone restricted fetal growth (Newnham
et al 1999), although offspring of both groups had altered glucose metabolism
postnatally (Moss et al 2001). In rats, last trimester glucocorticoid exposure
programmes permanent hyperglycaemia and hyperinsulinaemia in the adult offspring
(Nyirenda et al 1998). Again, the timing of exposure is important; earlier treatment
does not result in adult glucose intolerance.
1.3.2 Nutritional programming
Animal studies have shown that maternal undernutrition during pregnancy results in
reduced birth weight and a number of metabolic and cardiovascular sequelae. Rats
maintained on a low protein diet throughout pregnancy deliver offspring with
reduced birth weight, which develop glucose intolerance and hypertension in
adulthood (Langley et al 1994, Langley & Jackson 1994, Hales et al 1996). Other
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studies have demonstrated permanent effects of maternal protein restriction on the
endocrine pancreas (Snoeck et al 1990), the liver (Ozanne et al 1996a), and skeletal
muscle (Ozanne et al 1996b).
The role of undernutrition in fetal programming in humans is less clear. The effects
of malnutrition have been reported widely following the Dutch famine of 1944 -
1945, during which the Western Netherlands was affected by acute famine, a period
known as the 'Hunger Winter'. The famine ceased immediately with liberation in
May 1945, after which food supplies became abundant. Babies exposed to famine
during the last trimester were of lower birth weight and developed glucose
intolerance in adulthood (Ravelli et al 1998). However, not all studies show a strong
association between maternal undernutrition and later offspring disease. The siege of
Leningrad, which lasted from 1941 until 1944, led to a severe famine during which
up to one million people died, mainly of starvation. Average male and female birth
weights fell by up to 18% during this time. Despite this, individuals exposed to
famine in utero showed no difference in the prevalence of glucose intolerance,
dyslipidaemia, hypertension or cardiovascular disease in adulthood, when compared
with a similar group exposed to the same famine conditions in infancy, and a group
not exposed to famine (Stanner et al 1997). However, there are differences between
the Dutch and Leningrad famine survivors that may explain the differences found.
One of the major hypotheses advanced to explain this discrepancy suggests that the
lack of catch-up growth in children in the Leningrad population, which was
malnourished before and after the severe famine, may explain this apparent
protection from the programming effects seen in the Dutch cohort.
In developed countries, dietary deficiency is rarely thought to be a significant cause
of impaired fetal growth (Godfrey & Robinson 1998, Mathews et al 1999, Robinson
et al 2000). However, recent studies suggest that women with eating disorders are
more likely to give birth to low birth weight infants (Conti et al 1998). Although
dietary supplementation has been shown to increase birth weight in a study of
women in the Gambia (Ceesay et al 1997), most studies have only demonstrated a
small effect (Kramer & Kakuma 2003). Intriguingly, one small study in Guatemala
has demonstrated that nutritional supplementation of girls during early childhood
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may have a positive effect on the birth weight and height of their offspring (Stein et
al 2003).
Birth weight is influenced by maternal body composition as well as nutrition during
pregnancy (Barker 1998) and it is likely that fetal development may be influenced by
micronutrient as well as macronutrient deficiency (Boucher 1998). However, so far,
single micronutrient supplementation trials have generally not shown a significant
effect on birth weight (Fall et al 2003, Merialdi et al 2003).
1.3.3 A common mechanism?
Intriguingly, it is possible that glucocorticoid programming and maternal
undernutrition are linked by a common mechanism (Langley-Evans et al 1996c). The
enzyme 1 ip-hydroxysteroid dehydrogenase type 2 (lip-HSD 2) converts active
glucocorticoids to inactive products, is present in the placenta, and may act as a
barrier to protect the fetus from maternal glucocorticoids (Edwards et al 1993). In
rats, inhibition of this enzyme by carbenoxolone results in offspring of low birth
weight, with later glucose intolerance and high blood pressure (Lindsay et al 1996a,
Lindsay et al 1996b), a phenotype similar to that seen in rats exposed to
dexamethasone in utero (Benediktsson et al 1993, Nyirenda et al 1998). Reduced
placental lip-HSD 2 gene expression has been reported in human pregnancies
complicated by intra-uterine growth retardation (McTernan et al 2001), and rodent
studies have demonstrated that dietary restriction during pregnancy reduces placental
lip-HSD 2 expression and disturbs the neonatal HPA axis (Langley-Evans et al
1996c, Lesage et al 2001). Thus, maternal malnutrition potentially exerts




1.4.1 Intergenerational programming in humans
There is evidence that what appears to be inherited, and may therefore be assumed to
be due to genetic factors, may in fact, be due to a perpetuation of programming
effects across a number of generations. There is a well-recognised 'intergenerational
cycle of growth failure' in the developing world - young girls who grow poorly
become short women and are more likely to give birth to low birth weight babies. If
these infants are girls, they are likely to continue the cycle by being short in
adulthood and so on (Ramakrishnan et al 1999). It is possible that this apparent
intergenerational effect on fetal growth may also be important in the developed
world, and may contribute to adult cardiovascular disease in Westernised societies.
In 1986, Emanuel defined intergenerational influences as 'those factors, conditions,
exposures and environments experienced by one generation that relate to the health,
growth and development of the next generation' (Emanuel 1986). Epidemiological
studies have suggested that there may be intergenerational effects on birth weight
(Ounsted & Ounsted 1968, Johnstone & Inglis 1974, Klebanoff et al 1984, Emanuel
et al 1992, Hennessy & Alberman 1998, Collins et al 2002). If low birth weight is
associated with increased cardiovascular risk, this could lead to the 'inheritance' of a
predisposition to low birth weight and adverse cardiovascular risk across a number of
generations. A model is presented in figure 1.2.
Potential explanations for intergenerational effects include: a) that genetic attributes
may manifest themselves similarly in parent and offspring; b) that adverse extrinsic
environmental conditions may persist across generations; and c) that adverse in utero
experiences may permanently affect maternal growth and development, altering her
metabolism in such a way as to provide an adverse environment for her fetus. This
last hypothesis suggests a mechanism by which programming effects could be self-
























1.4.2 Intergenerational effects on birth weight
Studies in a number of different populations have demonstrated that offspring birth
weight is related to maternal birth weight (Ounsted & Ounsted 1968, Johnstone &
Inglis 1974, Klebanoff et al 1984, Carr-Hill et al 1987, Klebanoff et al 1989,
Emanuel et al 1992, Klebanoff et al 1997, Emanuel et al 1999, Collins et al 2002), an
effect which appears to act through reduced intrauterine growth rather than reduced
duration of gestation (Klebanoff et al 1984, Klebanoff et al 1997). In 1968, Ounsted
published data from a cohort of growth retarded and growth-accelerated infants taken
from the British Perinatal Mortality survey of 1958 suggesting a matrilineal pattern
of birth weight inheritance (Ounsted & Ounsted 1968) although the study was too
small to exclude a major contribution of the father to offspring birth weight.
Subsequently, extensive study of the 1958 birth cohort from the British National
Child Development Study showed a direct association between parental and
offspring birth weights (Alberman et al 1992, Emanuel et al 1992, Hennessy &
Alberman 1998), and assessment of grandparental data in these and other studies has
also provided evidence for a matrilineal multigenerational effect on birth weight
(Emanuel et al 1992, Klebanoff et al 1997). Although there is also a significant
relationship between paternal and offspring birth weight (Emanuel et al 1992,
Klebanoff et al 1998, Magnus et al 2001), this association is not as strong as that for
maternal birth weight (Alberman et al 1992, Emanuel et al 1992, Coutinho et al
1997, Klebanoff et al 1998).
Intergenerational effects on birth weight are also seen in the developing world.
Prospective studies in rural Guatemala found a clear relationship between maternal
and offspring birth weight, with an effect nearly twice that seen in developed
countries (Ramakrishnan et al 1999).
In addition, secular trends in birth weight may be mediated by intergenerational
factors. Studies in the US have identified differing intergenerational birth weight
effects among African-American and white populations in Illinois depending on
place of birth (Collins et al 2002), suggesting that environmental factors may be
influencing the secular trends in birth weight in populations with the same racial
background.
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1.4.3 Intergenerational effects on cardiovascular risk factors
The link between low birth weight and adult cardiovascular risk could be confounded
if both low birth weight and cardiovascular risk were inherited together. If this were
the case, then we might expect both parents to have an equal influence on the
inheritance of birth weight and later cardiovascular disease. However, there is much
evidence that parental influence is not equal and that the association of maternal
cardiovascular risk with offspring birth weight and cardiovascular risk is stronger
than the paternal association. A number of recent studies have explored the
relationship between parental cardiovascular risk and offspring characteristics and
several have demonstrated an association between offspring birth weight and
parental cardiovascular risk (Davey Smith et al 1997, Davey Smith et al 2000a,
Davey Smith et al 2000b, Smith et al 2001, Lawlor et al 2003a, Lawlor et al 2003b).
Whilst a further study showed no difference between maternal and paternal coronary
heart disease transmission to male offspring (Kinra et al 2003), others have shown a
stronger association with maternal cardiovascular disease (Davey Smith et al 1997,
Kuznetsova et al 2003).
There is a well-documented relationship between parental and offspring blood
pressure (Watt et al 1991, Walker et al 1998). There is also evidence that the
inheritance of low birth weight and hypertension may be linked. Mothers with higher
blood pressure in later life have been shown to deliver smaller babies, a relationship
that confounds that which is found between low birth weight and adult hypertension
(Walker et al 1998, Lawlor et al 2002). Women who were small for gestational age
are at increased risk of developing hypertension during pregnancy (Klebanoff et al
1999), and a number of studies have found that women with hypertension during
pregnancy are at increased risk of delivering low birth weight babies (Misra 1996,
Ferrer et al 2000, Brown et al 2001, Buchbinder et al 2002). Additionally, there is a
continuous inverse association between fetal growth and maternal blood pressure
across the range seen in normal pregnancy; higher maternal diastolic blood pressure
during later pregnancy is predictive of lower offspring birth weight (Churchill et al
1997). However, although paternal blood pressure is associated with offspring blood
pressure, it does not predict offspring birth weight (Walker et al 1998). Furthermore,
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lower maternal but not paternal birth weight is related to higher offspring blood
pressure, an association which is largely independent of the relationship between
maternal and offspring birth weight (Barker et al 2000).
There have been many studies of the association of parental diabetes with offspring
diabetes risk (Alcolado & Alcolado 1991, Thomas et al 1994, Klein et al 1996,
Viswanathan et al 1996, Karter et al 1999, Dabelea et al 2000, Lindsay et al 2000,
Meigs et al 2000, Yajnik et al 2001). Studies of women in the US Nurses study, and
those from Pima Native American populations have demonstrated that the offspring
of mothers with diabetes during pregnancy were at increased risk of developing type
2 diabetes (Pettitt et al 1993, Dabelea et al 2000, Lindsay et al 2000). A further study
involving 15,000 families showed a modest excess maternal transmission of type 2
diabetes in a multiethnic population in the US, although the relationships varied
between racial groups and appeared stronger in the female offspring (Karter et al
1999). A number of other studies have also reported excess maternal transmission of
type 2 diabetes (Alcolado & Alcolado 1991, Lin et al 1994, Thomas et al 1994,
Groop et al 1996, Klein et al 1996, Riley et al 1997, Bjornholt et al 2000), although
this has not been a consistent finding in all populations studied (Mitchell et al 1995,
McCarthy et al 1996, Viswanathan et al 1996, Meigs et al 2000).
The association between maternal diabetes, offspring birth weight and subsequent
diabetes is complex. Women of low birth weight are at increased risk of developing
gestational diabetes and type 2 diabetes (Williams et al 1999, Egeland et al 2000,
Forsen et al 2000, Innes et al 2002, Seghieri et al 2002). The offspring of women
with gestational and type 2 diabetes are more likely to be of higher birth weight
(Silverman et al 1991) and indeed, women of low birth weight who develop
gestational diabetes are at increased risk of delivering a macrosomic baby (Seghieri
et al 2002). Such offspring are themselves at risk of developing obesity (Pettitt et al
1993, Gillman et al 2003), gestational diabetes (Innes et al 2002) and type 2 diabetes
later in life (Pettitt et al 1993, Lindsay et al 2000, Catalano et al 2003). Consistent
with this, some studies have confirmed a U-shaped relationship between a woman's
risk for developing gestational diabetes and her own birth weight (Egeland et al
2000, Innes et al 2002).
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The Pima Indian Community has a high prevalence of maternal diabetes. In this
population, low birth weight is associated with the subsequent development of type 2
diabetes, but only if paternal diabetes is also present (Lindsay et al 2000). Maternal
diabetes is associated with an increased risk of type 2 diabetes in the offspring, but in
individuals with higher birth weight (Pettitt et al 1993, Dabelea et al 2000, Lindsay et
al 2000). A number of other studies have also shown paternal diabetes to be
associated with lower offspring birth weight (Yajnik et al 2001, Hypponen et al
2003), although others have found no such association (Rich-Edwards et al 1999). In
populations at high risk of type 2 diabetes it is possible that the relationship between
maternal diabetes and offspring birth weight and diabetes risk is obscured by the
effect of maternal metabolic disturbances on fetal growth (Pettitt et al 1993, Lindsay
et al 2000), but it has also been proposed that the association of low birth weight and
diabetes reflects the influence of genetic factors (Dunger et al 1998, Hattersley &
Tooke 1999). Indeed, it has recently been shown that in the Pima population, birth
weight shows linkage to chromosome 11, with evidence for an imprinted, paternally
expressed gene (Lindsay et al 2002a). There is, however, little evidence of parent-
specific linkage of diabetes to this chromosome, and indeed a number of genes
associated with insulin resistance are not associated with birth weight in the Pima
population (Lindsay et al 2002b).
Thus, although there are maternal and paternal effects on offspring birth weight and
susceptibility to type 2 diabetes and cardiovascular disease, which may be genetic,
there is evidence for a specific effect of maternal rather than paternal characteristics,
which may represent a process of intergenerational programming.
1.4.4 Intergenerational effects in animal models of programming
Extensive animal studies have attempted to dissect and validate the mechanisms of
the early life origins of disease (Benediktsson et al 1993, Seckl 1997, Seckl 1998,
Hoet & Hanson 1999, Challis et al 2001, Meaney 2001) and there is a substantial
body of evidence from these animal studies that programmed phenomena can be
perpetuated in later generations. Animal models of prenatal programming by
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nutrition or exercise, and postnatal programming by nutrition have shown effects on
birth weight (Stewart et al 1975, Pinto & Shetty 1995) and glucose tolerance (Martin
et al 2000, Patel et al 2001) in subsequent generations. Additionally, brief daily
handling of rats in the neonatal period, which results in decreased stress reactivity in
adulthood, is associated with intergenerational effects on the offspring hypothalamic-
pituitary axis (Francis et al 1999).
1.4.4.1 Programming of birth weight
Intergenerational effects of dietary manipulations on birth weight have been
demonstrated in black-and-white hooded rats (Stewart et al 1975). Colonies of rats
were maintained for 12 generations on a control diet or a diet marginally deficient in
protein. Birth weight was reduced in the first generation ofmalnourished animals and
this effect of poor maternal diet on birth weight appeared to be amplified in
subsequent generations. Mid-way through this intergenerational experiment a more
unpalatable diet was introduced by chance. Following this, further reduction in birth
weight was seen in the malnourished colony and in addition, there was a slight
reduction in birth weights in the control colony. After the re-introduction of more
palatable chow, birth weights in control animals increased, but did not return to
baseline for approximately three generations, despite the resumption of normal
nutrition. The study clearly demonstrates that continued poor maternal nutrition
produces amplified effects on birth weight through a number of generations.
However, the accidental introduction of less palatable food, which resulted in a
period of self-imposed calorie restriction in the 'control' animals, also provides
evidence that poor nutrition in one generation can produce effects on birth weight in
subsequent generations. This effect was confirmed in further experiments when a
number of animals from the malnourished colony weaned onto the control diet did
not achieve an adult size equivalent to that of the control animals for 3 further
generations (Stewart et al 1980).
Intergenerational effects on birth weight in rats have also been shown following
maternal exercise during pregnancy and lactation (Pinto & Shetty 1995). Exercise
during pregnancy (swimming) resulted in low birth weight first generation (Fl) pups.
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The second generation (F2) offspring of growth retarded F1 animals that were
sedentary during pregnancy were also found to be growth retarded, suggesting an
adverse intergenerational influence of maternal exercise stress on fetal growth in
these animals.
1.4.4.2 Programming of metabolic parameters and blood pressure
Recent studies have been able to demonstrate other intergenerational effects in
animal models. Fetal undernutrition can produce effects on glucose homeostasis in a
second (F2) generation of rats (Martin et al 2000). Intergenerational effects on birth
weight and the endocrine pancreas have also been reported following the use of a
low protein, isocaloric diet (Hoet & Hanson 1999).
Intergenerational effects on blood pressure in rabbits has recently been demonstrated
in an experiment in which females with surgically induced hypertension were mated
with normotensive males (Denton et al 2003). The female offspring of hypertensive
rabbits had increased blood pressure as adults when compared with the offspring of
sham-operated females, although blood pressure in male offspring was unaffected
(Denton et al 2003).
1.4.4.3 Postnatal programming
Postnatal programming may also have intergenerational effects. Overfeeding in the
neonatal period has been shown to produce second generation effects on glucose
homeostasis (Laychock et al 1995, Vadlamudi et al 1995, Patel et al 2001, Srinivasan
et al 2003).
Additionally, post-natal environmental manipulations programming the
hypothalamic-pituitary-adrenal (HPA) axis stress response may produce
intergenerational effects. A number of studies suggest that differences in behavioural
and neuroendocrine responses to stress may be transmitted from one generation to
another by non-genomic mechanisms (Meaney 2001). In rodents, naturally occurring
variations in maternal behaviour are associated with different HPA stress
responsiveness in offspring (Liu et al 1997). Cross-fostering studies have
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demonstrated that such differences in maternal behaviour, and therefore differences
in offspring stress reactivity, may be transmitted across generations by non-genomic
mechanisms (Francis et al 1999). Additionally, postnatal handling of rat pups is
associated with programming of the HPA axis; handled offspring show reduced HPA
responses to stress and increased maternal care behaviour (Francis et al 1999).
Again, these individual differences in maternal behaviour and HPA responses can be
transmitted from one generation to another (Francis et al 1999).
1.5 Mechanisms of intergenerational inheritance
From the above, it is clear that intergenerational programming can occur, even in the
absence of a continuing environmental stimulus. This would suggest that permanent
'programming' ofmaternal physiology might lead to the persistence of programming
effects across a number of generations. Such effects might be apparently
advantageous, as in the secular changes of increasing birth weight across generations
which has been documented in some populations (Chike-Obi et al 1996, Skjaerven et
al 2000, Kramer et al 2002), or deleterious, as in the perpetuation of low birth weight
and higher blood pressure (Barker et al 1989, Walker et al 1998). Why might the
environmental experience of one generation affect the offspring of subsequent
generations, and how might such intergenerational effects be mediated?
1.5.1 Maternal growth
Exposure of the fetus to an adverse environment in utero may lead to permanent
alterations in physiology in adulthood. Such physiological changes may result in an
adverse intrauterine environment for the offspring of the individual, leading to
physiological changes in the next generation and so on. There is evidence that poor
maternal intrauterine growth is associated with reduced weight gain during
pregnancy (Hackman et al 1983), suggesting that pregnancy may be affected by
physiological changes consequent on poor maternal growth. The importance of
maternal size in determining the intrauterine growth of offspring has been
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demonstrated with cross breeding experiments in Shetland ponies and Shire horses
(Walton & Hammond 1938). The offspring were smaller when the Shetland pony
rather than the Shire horse was the mother, suggesting that maternal size has an
important influence on the size of the offspring. Indeed, short women have small
babies (Cawley et al 1954), and British mothers whose stature equalled or exceeded
that predicted from midparental height had bigger babies than mothers of smaller
stature (Emanuel 1997). Animal studies have shown that organ size is affected by
intrauterine malnutrition (Stewart et al 1975), and girls born small for gestational age
and remaining small have reduced uterine and ovarian size (Ibanez et al 2000).
However, the growth retarded babies most likely to develop adult cardiovascular risk
factors are those who catch up most in terms of growth in childhood. These mothers
will not, therefore, be small at the time of conceiving the next generation, suggesting
that maternal size is unlikely to account for intergenerational programming of
cardiovascular risk.
1.5.2 Socio-economic factors
Socio-economic factors may have a role in intergenerational effects. Lifelong
minority status and disadvantage amongst black women in the USA may have played
a key part in perpetuating poor intrauterine growth across a number of generations
(Collins et al 2002). In two Swedish cohorts born in the 1920s and in 1985,
household social class was shown to have a clear influence on birth weight (Vagero
& Leon 1994). However, social class is (at least conventionally), as much influenced
by paternal as by maternal circumstances, so is unlikely to account for matrilineal
inheritance.
Conversely, improvements in the environment and in maternal health could also have
intergenerational effects on offspring growth. Secular trends in some populations
show increases in mean birth weight of 40 - lOOg over decades (Chike-Obi et al
1996, Skjaerven et al 2000, Collins et al 2002). Such a rapid increase in the mean
population birth weight provides evidence of the importance of environmental
factors in the expression of genetic potential.
19
1.5.3 Nutrition
One of the major factors proposed to explain fetal programming is maternal
undernutrition, and studies in humans and animals suggest that this may have
intergenerational consequences. In developing countries, maternal diet can have an
effect on birth weight, and may be important in mediating intergenerational effects
on birth weight and adult disease. Such effects may also be mediated, or indeed
amplified, by adverse environmental conditions persisting across a number of
generations. In animal models, second generation effects have been noted following
impaired nutrition in utero, and exposure during specific time-windows of
development may be important (Stewart et al 1975, Stewart et al 1980, Laychock et
al 1995, Hoet & Hanson 1999, Martin et al 2000). However, these occur even when
nutrition is normal in the F2 generation, so that perpetuation of the insult may not be
required to express the effect in later generations.
Early results from the 1944-1945 Dutch famine studies suggested that there may be
second generation effects following a specific environmental insult in a previously
healthy population (Lumey 1992). Initial studies suggested that mothers with first
and second trimester exposure to famine had offspring (F2) of lower birth weights
than those not exposed to famine (Lumey 1992). However, this study was flawed in a
number of ways, including that birth weights in famine-exposed mothers were not
directly ascertained but were extrapolated from another group. A subsequent study
found no significant effect of maternal famine exposure on their F2 offspring birth
weight (Stein & Lumey 2000).
One small study in Guatemala has demonstrated that nutritional supplementation of
girls during early childhood may have a positive effect on the birth weight and height
of their offspring (Stein et al 2003), however, as discussed earlier, the role of dietary
deficiency in the association between poor fetal growth and later disease in
developed countries is unclear. The role of impaired nutrition in intergenerational
effects on birth weight and cardiovascular risk therefore remains uncertain, but may




Animal studies have shown that antenatal glucocorticoids can lead to a number of
programming effects, including low birth weight, hypertension, glucose intolerance
and elevated plasma glucocorticoid levels (Nyirenda et al 1998, Newnham 2001) and
data from human studies suggest that prenatal glucocorticoid exposure lowers birth
weight and is associated with increased blood pressure in humans (Doyle et al 2000,
Bloom et al 2001). Furthermore, in animal models (Levitt et al 1996, Welberg et al
2000) and in humans (Phillips et al 1998, Levitt et al 2000, Reynolds et al 2001),
plasma glucocorticoids are elevated in adults born with lower birth weight. Elevated
glucocorticoid levels might potentially mediate both lower birth weight and
hypertension through a number of generations.
1.5.5 Blood pressure
Other possible mechanisms underlying intergenerational effects include
haemodynamic changes, which may be self-perpetuating in subsequent generations.
One such mediator of this effect may be blood pressure; lower maternal birth weight
is associated with an increased risk of hypertension during pregnancy (Klebanoff et
al 1999) and higher maternal blood pressure during pregnancy is associated with
lower offspring birth weight (Churchill et al 1997, Ferrer et al 2000, Brown et al
2001, Buchbinder et al 2002), and with higher offspring blood pressure (Walker et al
1998). In addition, maternal birth weight is related to offspring blood pressure
(Barker et al 2000). Although one study found that the association between maternal
birth weight and offspring blood pressure was independent of maternal blood
pressure later in life (Barker et al 2000), this apparent inherited effect may represent
intergenerational influences on fetal programming, with low birth weight and
subsequent higher blood pressure influencing fetal growth in such a way as to
perpetuate this phenomenon. Indeed this is supported by a recent study
demonstrating higher blood pressure in the female offspring of rabbits with
secondary hypertension (Denton et al 2003).
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1.5.6 Epigenetic mechanisms
Epigenetic modification of the genome is thought to be important in maintaining
different patterns of gene expression in different cell groups, in the establishment of
parental genomic imprints in germ cells (parental imprinting), and in the erasure of
epimutations (Rakyan et al 2001). Epigenetic control of gene expression is likely to
be mediated by alterations in DNA methylation and/or modifications of chromatin
packaging, possibly via changes in histone acetylation. Both mechanisms may
influence transcriptional activity and thus gene expression, mainly by the
transcriptional silencing of the modified allele (Rakyan et al 2001). Such
modifications influence gene expression, are established early in development and
maintained throughout life and may affect the phenotype without changing the DNA
sequence, making them prime candidates to explain programming. Epigenetic
modification is not restricted to parentally imprinted genes, and the variable
expression of some identical alleles within a population may therefore be due to
epigenetic modulation rather than genetic differences or adult environmental
influences (Rakyan et al 2001).
A number of genes important in modulating fetal growth, particularly those involved
in the control of the expression of IGF2, are imprinted; indeed, loss of imprinting of
the IGF2 gene in humans leads to Beckwith-Wiedemann syndrome, associated with
fetal overgrowth (Morison & Reeve 1998). In addition, IGF2 and a number of related
genes are imprinted in the placenta (Young 2001) and it has been proposed that the
IGF2 gene and perhaps others may control the placental supply of nutrients to the
fetus, and thus affect fetal growth (Constancia et al 2002, Reik et al 2003). In mice,
manipulations leading to alterations in the expression of imprinted genes in fetal
tissues and in the placenta have been shown to be associated with alterations in fetal
growth (Reik et al 2003). Imprinting of genes has been proposed as the mechanism
behind the association of lower offspring birth weight with paternal diabetes in the
Pima Indian population (Lindsay et al 2000, Lindsay et al 2002a), and in the parental
differences seen in the transmission of class III alleles of the variable number tandem
repeat minisatellite 5' to the insulin gene (INS-VNTR), variations in which have
been associated with type 2 diabetes (Huxtable et al 2000).
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The epigenetic silencing of one allele of a gene according to the parent of origin, or
parental imprinting, is erased through meiosis and re-established in the offspring.
However, recent evidence suggests that epigenetic modifications at some other
alleles may not be completely erased during gametogenesis and embryogenesis,
potentially resulting in the intergenerational inheritance of the epigenetic state
(Roemer et al 1997, Morgan et al 1999). Very recently it has been shown in mice that
the variable expressivity of an allele affecting tail development corresponds with
differential methylation which shows transgenerational epigenetic inheritance after
both paternal and maternal transmission, displays parent of origin effects (the
penetrance of the abnormal tail phenotype is greater after paternal transmission) and
is influenced by the strain background (Rakyan et al 2003).
Imprinting of genes can be modified by environmental factors (Reik et al 2003) and
imprinted genes may be more vulnerable to methylation changes than the rest of the
genome (Young 2001). Embryo culture experiments have shown that environmental
influences can permanently affect gene expression and have profound effects on
growth (Reik et al 1993, Dean et al 1998, Khosla et al 2001, Young et al 2001).
Manipulations of the culture medium of the pre-implantation embryo can result in
fetal overgrowth in sheep, in association with reduced methylation and a consequent
reduction in expression of the IGF2R gene (Young et al 2001). In mice, alterations in
the culture medium can result in a reduction in fetal weight associated with reduced
expression of IGF2 and HI9 (Khosla et al 2001). These effects on fetal growth
perhaps represent epigenetic mechanisms. Intriguingly, many growth factors
including IGF2, are regulated by glucocorticoids in fetal and adult tissues in vivo and
in vitro (Luo et al 1990, Li et al 1993, Miell et al 1994, Mouhieddine et al 1996,
Forhead et al 1998, Li et al 2002). Offspring IGFs are also affected by maternal
nutrition in rats (Woodall et al 1996a, Petrik et al 1999) and in humans (Barker et al
1993a). Very recently, altered maternal diet during pregnancy has been shown to
increase methylation of the agouti gene and alter the phenotype of Agouti Yellow
mouse pups. These mice are obese and yellow, due to a mutation in the agouti gene,
however pups born to mothers supplemented with vitamins (methyl donors) during
pregnancy were found to be thin and brown, and had increased methylation at the
agouti locus (Waterland & Jirtle 2003), reducing expression of the mutant allele.
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Thus, environmental factors including nutrition and glucocorticoids could potentially
influence the expression of genes, affecting fetal growth and later disease risk. If
such epigenetic modifications were not erased during gametogenesis and
embryogenesis, this could lead to the transgenerational inheritance of 'programmed
effects' (Reik et al 2003). Indeed, nutrition mediated epigenetic effects have been
proposed as a mechanism to explain the apparent transgenerational inheritance
through the male line of cardiovascular disease and diabetes risk described in
Swedish men (Kaati et al 2002, Pembrey 2002). Furthermore, evidence is emerging
for selective methylation/demethylation of specific promoters of the glucocorticoid
receptor (GR) gene in association with variations in maternal care (Weaver et al
2002) which also appear to be inherited.
1.6 The amplification of programming by obesity
The development of obesity appears to be an important factor modifying the risk of
later disease associated with low birth weight. Those with low birth weight but who
demonstrate catch-up growth in early childhood, appear to be at the highest risk of
later obesity (Dietz 1994, Ong et al 2000, Eriksson et al 2003) and those individuals
with the lowest birth weight but highest current weight have the highest total body
fat (Gale et al 2001). Thus, low birth weight appears to be a risk factor for the
development of obesity during childhood and adulthood and a number of human
studies have demonstrated that this increases the risk of later disease. In the Preston
cohort, insulin resistance was shown to be greatest in those of low birth weight with
highest body mass later in life (Phillips et al 1994). In Swedish men, low birth weight
was found to be associated with an increased risk of type 2 diabetes and higher blood
pressure, with an effect most marked in those who subsequently became obese (Leon
et al 1996, Lithell et al 1996). Low birth weight followed by high growth rates after
the age of 7 years and a high body mass index (BMI) in childhood is associated with
coronary heart disease in men and type 2 diabetes in women in Finland (Eriksson et
al 1999, Forsen et al 2000, Eriksson et al 2001). Intriguingly, two patterns of growth
were associated with later disease risk, those of low birth weight who remained thin
in childhood but became obese as adults had an increased risk of insulin resistance,
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whereas those of low birth weight who demonstrated rapid childhood growth, had a
high BMI in childhood and who remained obese as adults were at increased risk of
developing type 2 diabetes (Eriksson et al 2002, Eriksson et al 2003). In another UK
cohort, low birth weight and accelerated weight gain in childhood were associated
with the highest adult blood pressure (Law et al 2002).
The long-term effects of malnutrition in utero have been studied in the Leningrad
Siege and the Dutch Famine Studies. In the Leningrad siege study, a positive
association between obesity and blood pressure was found, with a relationship that
was strongest in those exposed to malnutrition in utero during the siege (Stanner et al
1997, Stanner & Yudkin 2001). Among 19-year-old men exposed to the Dutch
famine, those exposed during the first half of pregnancy had a higher risk of obesity
than those exposed during later pregnancy (Ravelli et al 1976). Among 50-year-olds,
women exposed to famine in early gestation had a higher BMI and waist
circumference than unexposed women (Ravelli et al 1999). Furthermore, prenatal
exposure to famine is linked to decreased glucose tolerance in adulthood, particularly
in those who become obese (Ravelli et al 1998).
The prevalence of obesity, type 2 diabetes and cardiovascular disease is increasing
rapidly in urban India (Yajnik 2002). Indian babies are of lower birth weight than
Caucasian babies, but have a similar subscapular skin fold thickness, suggesting a
lower lean body mass (Yajnik 2002, Yajnik et al 2002). In addition, Indian babies
appear to be hyperinsulinaemic (Yajnik et al 2002). In childhood, the highest levels
of insulin resistance syndrome variables and total and LDL cholesterol were in those
children of low birth weight who had a high fat mass at 8 years (Bavdekar et al
1999). Furthermore, among Indians in rural and urban communities, low birth weight
and central obesity in adulthood was found to be associated with increased
cardiovascular risk (Yajnik 2002).
The importance of obesity as an amplifier of programming effects has been explored
in a number of animal models in which antenatal nutritional manipulations have
resulted in offspring of low birth weight and postnatal growth failure. Rats which
were exposed to maternal undernutrition throughout gestation, which were then
cross-fostered onto normally nourished mothers and subsequently weaned on to a
hypercaloric diet demonstrated amplified metabolic and cardiovascular
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abnormalities, developing hyperphagia, profound obesity, hyperglycaemia,
hyperinsulinaemia, hyperleptinaemia and hypertension (Vickers et al 2000, Vickers
et al 2001b). Rats exposed to pre- and postnatal protein restriction which were
exposed to a high fat diet at 20 weeks of age developed glucose intolerance as a
result of impaired insulin secretion and peripheral insulin resistance, in contrast to
those maintained on the low protein diet which demonstrated impaired insulin
secretion, but maintained glucose tolerance by increasing peripheral insulin
sensitivity. A further control group exposed to a high fat diet only, developed
peripheral insulin resistance, but were able to maintain normoglycaemia as a result of
increased insulin secretion (Holness & Sugden 1999).
Thus, in humans, adult body size appears to be an important modifying factor in the
association between low birth weight and subsequent disease risk, and animal models
demonstrate that postnatal dietary manipulations can amplify the metabolic and
cardiovascular sequelae of fetal programming.
1.7 Glucocorticoids
Having reviewed the evidence for fetal programming and the potential mechanisms
underlying intergenerational effects in humans and animal models, the rest of the
introduction will now review glucocorticoid synthesis, secretion and metabolism and
consider the evidence that glucocorticoids play a key role in the development of the
programmed phenotype. Finally, glucocorticoid action and the role of
glucocorticoids in obesity will be discussed.
1.7.1 Synthesis, transport and metabolism
Glucocorticoids are steroid hormones that are synthesised in the mitochondria and
endoplasmic reticulum of cells in the zona fasciculata and zona reticularis in the
adrenal cortex. All steroid hormones have the same basic structure of three
cyclohexane rings and a single cyclopentane ring. Cholesterol, most of which is
derived from circulating low-density lipoprotein (LDL) cholesterol, is the precursor
for all adrenal steroidogenesis, which involves the action of several enzymes
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including a number of the cytochrome p450 family (Figure 1.3). The molecular
structures of the major active glucocorticoids (Cortisol in man, corticosterone in rats)
are depicted in figure 1.3. Over 90% of circulating Cortisol and corticosterone are
bound to albumin or the high affinity corticosteroid-binding globulin (CBG)
(Flammond 1990), an a,2-globulin synthesised in the liver. Only the remaining free
circulating hormone is available for transport into tissues and is biologically active.
The half-life of these circulating steroids is around 90 minutes, and the metabolism
involves a number of steps, which are shown in figure 1.4. Cortisol (corticosterone)
and cortisone (11-dehydrocorticosterone) are interconverted by the isoenzymes of
1 ip-hydroxysteroid dehydrogenase (1 ip-HSD 1 and 2); their subsequent metabolism
follows similar steps. Firstly, the C4-C5 double bond is reduced by either 5a- or 5p~
reductase, to give dihydro-metabolites. Cortisol (F) and corticosterone (B) can be
metabolised by either 5a- or 5p-reductase, whereas cortisone (E) and 11-
dehydrocorticosterone (A), are only metabolised by 5P-reductase. The dihydro-
metabolites are then rapidly reduced by 3a-hydroxysteroid dehydrogenase (3a-
HSD), to give the tetrahydro-metabolites: in the case of Cortisol and cortisone, 5a-
tetrahydrocortisol (allo-THF), 5p-tetrahydrocortisol (THF) and 5p-
tetrahydrocortisone (THE); and for the rodent steroids, 5a- and 5P~
tetrahydrocorticosterone (5a- and 5P-THB) and 5p-tetrahydro-l 1-
dehydrocorticosterone (5P-THA). Further reduction of the 20-oxo group then occurs
(by 20a- or 20p-hydroxysteroid dehydrogenase), to yield the cortols and cortolones.
Oxidation of these compounds by 21-oxidase yields cortolic and cortolonic acids. In
humans, approximately 50% of the secreted glucocorticoids are excreted in the urine
as tetrahydro-metabolites, which are conjugated with glucuronic acid to increase
water solubility.
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Figure 1.4 Routes of Cortisol metabolism in vivo
Both 5a- and 5(3-reduction of Cortisol occur, but cortisone is only acted on by 5P-
reductase.
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1.7.2 The Hypothalamic-pituitary-adrenal (HPA) axis
The secretion of glucocorticoids is regulated by the HPA axis (Figure 1.5).
Adrenocorticotrophic hormone (ACTH) is the principal hormone stimulating the
production of glucocorticoids in the adrenal. The polypeptide hormone ACTH is
produced in the corticotrophs of the anterior pituitary, where it is formed from the
cleavage of a larger precursor, pro-opiomelanocortin (POMC). ACTH binds to its
receptor on the adrenal cortex cell surface, which is coupled to adenylate cyclase.
The subsequent increase in intracellular cyclic adenosine monophosphate (cAMP),
leads to steroidogenic acute regulatory (stAR) protein-mediated uptake of cholesterol
into mitochondria for steroidogenesis. In addition, chronic stimulation with ACTH
leads to an increase in the steroidogenic CYP enzymes (Waterman & Bischof 1997).
The secretion of ACTH is controlled by corticotrophin-releasing hormone (CRH)
and arginine vasopressin (AVP), synthesised in the paraventricular nucleus (PVN) of
the hypothalamus. CRH, AVP, ACTH and Cortisol are released in a pulsatile manner,
with a circadian rhythm, regulated by the suprachiasmatic nucleus of the
hypothalamus. In humans, levels are highest before waking and decline through the
day; in rats peak levels are achieved in the evening. Glucocorticoids exert a negative
feedback effect at the level of the hypothalamus by inhibiting CRH and AVP
synthesis in the PVN, and at the pituitary by inhibiting POMC gene transcription
(Keller-Wood & Dallman 1984, Davis et al 1986, Eberwine et al 1987, Roberts et al
1987). The regulation of glucocorticoid secretion is also influenced by input from
higher centres, particularly the hippocampus (Jacobson & Sapolsky 1991).
Studies in animal models indicate that the HPA axis is an important target for
glucocorticoid programming. Prenatal dexamethasone exposure or 11 (3-HSD 2
inhibition permanently increases basal plasma corticosterone levels in adult rats
(Levitt et al 1996, Welberg et al 2001). Both long- and short-term in utero exposure
to dexamethasone is associated with elevated basal plasma corticosterone levels,
however the underlying mechanisms differ depending on the timing and extent of
exposure. Exposure to dexamethasone during the last third of pregnancy reduces MR
and GR levels in the hippocampus and increases CRH mRNA in the hypothalamic
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paraventricular nucleus (PVN) (Levitt et al 1996, Welberg et al 2001). In contrast,
dexamethasone throughout gestation does not alter hippocampal GR or MR, but
increases receptor expression in the amygdala, a structure which stimulates the HPA
axis (Welberg et al 2001). Thus, in the rat, late gestational dexamethasone exposure
may permanently alter the 'set point' of the HPA axis at the level of the
hippocampus, reducing feedback sensitivity, whereas continuous exposure may
increase forward drive of the HPA axis through the amygdala.
In sheep, exposure to betamethasone alters HPA feedback sensitivity (Sloboda et al
2002a), with the outcome depending on the timing of exposure and whether
betamethasone was administered to the mother or directly to the fetus (Sloboda et al
2002a). Studies in guinea pigs also demonstrate altered HPA responses after prenatal
glucocorticoid exposure (Dean et al 2001, Liu et al 2001), although the effects are
smaller, probably because these animals are relatively glucocorticoid resistant
because of a mutant GR gene (Keightley & Fuller 1994). Finally, in primates, the
offspring ofmothers treated with dexamethasone during late pregnancy had elevated
basal and stress-stimulated Cortisol levels and a 30% reduction in hippocampal size
(Uno et al 1994). These studies in rodents, guinea pigs, sheep and primates indicate
that exposure to excess glucocorticoids in utero can programme HPA axis function.
Intriguingly, maternal undernutrition in rats (Langley-Evans et al 1996a) and sheep
(Hawkins et al 2000) also affects adult HPA axis function, suggesting that HPA
programming may be a common outcome of prenatal environmental challenge,
perhaps acting in part via alterations in placental lip-HSD 2 activity which is
selectively down-regulated by maternal dietary constraint (Langley-Evans et al
1996b, Bertram et al 2001).
1.7.3 The 1ip-hydroxysteroid dehydrogenase enzymes
The pre-receptor metabolism of glucocorticoids is thought to be an important means
ofmodulating local glucocorticoid action, by regulating the access of hormone to the
receptor. The isoenzymes of lip-HSD catalyse the interconversion of active
glucocorticoids (Cortisol and corticosterone) and their inactive 11-keto forms
(cortisone and 11-dehydrocorticosterone). The lip-HSDs are microsomal enzymes
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that belong to the short-chain alcohol dehydrogenase superfamily (Stewart &
Krozowski 1999, Seckl & Walker 2001).
1.7.3.1 11/3-hydroxysteroid dehydrogenase type 2
11 P-HSD 2 is a high affinity NAD-dependent dehydrogenase that inactivates Cortisol
and corticosterone. It is principally sited in mineralocorticoid target tissues such as
the kidney, colonic mucosa, salivary glands and sweat glands, but is also found in
placenta, lung, lymph nodes and vascular endothelium (Stewart & Krozowski 1999).
In the kidney, it primarily colocalises with the mineralocorticoid receptor (MR) and
acts to protect these receptors from illicit occupation by glucocorticoids, which
circulate at much higher concentrations than mineralocorticoids and bind with equal
affinity. 11 P-HSD 2 is also present in the placenta (Stewart et al 1995, Brown et al
1996a, Waddell et al 1998), where it is thought to be important in protecting the fetus
from the high circulating concentrations ofmaternal glucocorticoids.
1.7.3.2 11p-hydroxysteroid dehydrogenase type 1
lip-HSD 1 is a lower affinity NADP(H)- dependent enzyme, which is found in
many tissues, including brain, liver, adipose tissue, lung, vascular smooth muscle,
gonads and the adrenal cortex (Stewart & Krozowski 1999). Original investigations
found this enzyme to be bi-directional, with both reductase and dehydrogenase
activity, although the reductase activity was unstable in vitro (Lakshmi & Monder
1988). More recent studies have demonstrated that the enzyme is predominantly a
reductase when studied in intact cells or tissues in vitro or in vivo, but the
dehydrogenase direction is preferred when cells are disrupted (Jamieson et al 1995,
Rajan et al 1996, Bujalska et al 1997, Ricketts et al 1998, Jamieson et al 2000).
Isolated rat liver models demonstrate that the 11P-HSD 1 enzyme is a predominant
lip-reductase, and regenerates active glucocorticoids from their inactive metabolites
(Jamieson et al 2000). It has therefore been hypothesised that 11 p-HSD 1 is
important in maintaining local concentrations of glucocorticoid, in particular in those
tissue in which glucocorticoids play important roles in metabolic regulation. There is
32
some evidence to support this hypothesis; inhibition of lip-HSD 1 by chronic
oestrodiol administration inhibits the expression of glucocorticoid-induced
gluconeogenic enzymes (Jamieson et al 1999b) and transgenic mice with a targeted
disruption of the 1 1 P-HSD 1 gene are unable to convert 11-dehydrocorticosterone to
corticosterone following adrenalectomy (Kotelevtsev et al 1997). Furthermore, these
11P-HSD 1 knockout mice have a phenotype compatible with impaired
glucocorticoid regeneration despite elevated basal corticosterone concentrations; they
have impaired induction of PEPCK and glucose-6-phosphatase on fasting and resist
hyperglycaemia on exposure to stress or obesity (Kotelevtsev et al 1997).
Factors influencing lip-HSD 1 include glucocorticoids (Voice et al 1996), CRH and
ACTFI (Friedberg et al 2003), cytokines including TNFa (Tomlinson et al 2001,
Friedberg et al 2003), thyroid hormones (Whorwood et al 1993), sex steroids and GH
(Low et al 1993, Low et al 1994), IGF-1 and insulin (Voice et al 1996, Whorwood et
al 2001). Chronic stress or elevated glucocorticoid levels are associated with reduced
11 P-HSD 1 activity (Jamieson et al 1999a). In addition, both PPARa and PPARy
agonists attenuate 11 P-HSD 1 activity (Hermanowski-Vosatka et al 2000, Berger et
al 2001).
In fetal sheep, exposure to excess glucocorticoid increases hepatic 11 P-HSD 1
mRNA and protein (Yang et al 1995, Sloboda et al 2002b), however studies in the rat
have not shown any alterations in 11 P-HSD 1 activity in the liver of adult rats
exposed to dexamethasone in utero (Nyirenda et al 1998) and antenatal











11P-HSD 1 11P-HSD 2
11-dehydrocorticosterone
Figure 1.5 The HPA axis in rodents, depicting sites of negative feedback.
CRH = corticotrophin releasing hormone; ACTH = adrenocorticotrophic
hormone; AVP = arginine vasopressin
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1.7.4 The glucocorticoid receptor
The glucocorticoid receptor (GR) is a member of the nuclear hormone receptor
superfamily of ligand-activated transcription factors. These have a common
functional domain structure comprising a variable amino-terminal (N-terminal)
region, a central DNA binding domain; important for interaction with specific target
gene sequences, DNA induced homodimerisation and transcriptional activation, and
a carboxy-terminal (C-terminal) ligand-binding domain. The N-terminal and C-
terminal domains have additional transcription activation functions; the ligand-
binding domain also has a hormone-dependent dimerisation function and a hormone
dependent nuclear localisation signal.
The human GR (hGR) gene contains 9 exons; exon 1 and the first part of exon 2
contain the 5' untranslated region (5'UTR) and exons 2-9 contain the coding
sequences (Encio & Detera-Wadleigh 1991). Three different hGR mRNAs have been
identified. GRa and GRP both contain exons 1-8 but have different versions of exon
9 as a result of alternative splicing and encode the hGRa and hGRp receptor
isoforms (Hollenberg et al 1985); a third hGR mRNA is thought to encode hGRa.
Human GRa and GRp protein differ after amino acid 727 and in addition, alternative
translation initiation results in two different isoforms (A and B), of hGRa (Yudt &
Cidlowski 2001).
In the absence of ligand, GRa exists in a cytoplasmic complex with other proteins
including hsp90. On ligand binding, GRa dissociates from this complex and
translocates to the nucleus, where the receptor-ligand complex undergoes
dimerisation and binds to specific DNA sequences known as glucocorticoid-
responsive elements (GREs) in the promoter region of target genes. Binding ofGRa
to GREs leads to transcription initiation, however the mechanisms of this are not
fully understood. The transcriptional activity of GRa also depends on interaction
with other transcription factors (Gottlicher et al 1998) and various co-activators and
co-repressors (Sheppard et al 1998, Collingwood et al 1999, Glass & Rosenfeld
2000, Jenkins et al 2001). Such interactions facilitate recruitment of the basal
transcription machinery and/or lead to chromatin remodelling, leading to activation
or repression of target genes. Many glucocorticoid responsive genes have now been
35
identified, including many involved in carbohydrate and lipid metabolism (Stewart
2003).
Recently there has been increasing interest in the possibility that very rapid
corticosteroid effects may be mediated by membrane bound or associated forms of
GR, however the mechanisms of such effects remain to be determined (Iwasaki et al
1997, Chenet al 1999).
1.7.5 Regulation of GR expression
Glucocorticoid receptors are expressed in most cells, however expression and
sensitivity to glucocorticoids varies between individuals, tissues and cell types
(Herman et al 1989, Lim-Tio et al 1997). The level of expression of GR is critical for
cell function, indeed, transgenic mice with a reduction of 30-50% in tissue levels of
GR have major neuroendocrine, metabolic and immunological abnormalities (Pepin
et al 1992, King et al 1995). In the rat, prenatal dexamethasone exposure leads to
tissue-specific alterations in GR, which are thought in part, to explain the adult
phenotype of the dexamethasone-programmed animal; GR expression is permanently
increased in the periportal zone of the liver, in the amygdala, in adipose tissue and in
some muscle fibre types (Nyirenda et al 1998, Welberg et al 2001, Cleasby et al
2003a), but reduced in the hippocampus (Levitt et al 1996, Welberg et al 2001). In
addition to its interactions with transcription factors, co-activators, co-repressors and
a number of cytosolic proteins, a number of potential mechanisms exist for the
regulation of GR expression. Binding sites for a number of transcription factors have
been identified in the GR promoter region, which may permit cell type- and tissue
specific regulation of GR (reviewed in Yudt & Cidlowski 2002) and GR may
undergo post-translational modification (Yudt & Cidlowski 2002). Glucocorticoids
themselves appear to regulate GR expression, possibly through effects on
transcription, mRNA stability and protein stability (Schaaf & Cidlowski 2003). In
addition, GR(3 is thought to act as a dominant-negative inhibitor ofGRa (Bamberger
et al 1995, Oakley et al 1996, Oakley et al 1999), although its role in disease or
glucocorticoid resistance remains unclear (Schaaf & Cidlowski 2003).
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Tissue-specific expression patterns may also be achieved by the use of alternate
promoters (McCormick et al 2000, Breslin et al 2001). Multiple translation initiation
sites have been identified in exon 1 in rats (McCormick et al 2000), mice (Strahle et
al 1992) and humans (Breslin et al 2001). These give rise to a number of GR mRNAs
with different 5' untranslated regions within exon 1, which are spliced onto the
common translated sequence beginning at exon 2. In the rat, two of the alternate
exons are present in all tissues which have been studied, however others are tissue-
specific (McCormick et al 2000). This permits considerable complexity of tissue-
specific variation in the control of GR expression, indeed, first exon usage appears to
be altered by perinatal environmental manipulations (McCormick et al 2000).
1.7.6 Effects of glucocorticoids
1.7.6.1 Effects of glucocorticoids on metabolism
Glucocorticoids act to increase blood glucose concentrations by a number of
mechanisms. Cortisol stimulates glycogen synthesis by stimulating glycogen
synthase and inhibiting glycogen breakdown and additionally, increases hepatic
gluconeogenesis by stimulating the key gluconeogenic enzymes
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase. In
addition, peripheral uptake and utilisation of glucose by muscle and fat is reduced.
Glucocorticoids also have a permissive effect on the action of other hormones
including catecholamines and glucagon.
Glucocorticoids stimulate lipolysis, with the release of free fatty acids and glycerol.
Adipocyte differentiation is stimulated through the transcriptional activation of a
number of key genes, and in situations of glucocorticoid excess, this results in a
predominant increase in visceral fat, possibly due to the increased expression of GR
and 1 ip-HSD 1 in this fat depot.
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1.7.6.2 Effects on blood pressure
Glucocorticoids act to increase blood pressure by a number of mechanisms. They
have a permissive effect to potentiate the vascular response to catecholamines,
(particularly noradrenaline) and angiotensin II. Glucocorticoids inhibit nitric oxide
synthase, thereby reducing nitric oxide-mediated endothelial dilatation and act in the
distal nephron of the kidney to promote sodium and water retention.
1.7.6.3 Growth and development
Glucocorticoids accelerate the development of a number of organs in the developing
fetus and are widely exploited in obstetric practice to accelerate lung development in
threatened preterm labour. However, glucocorticoids in excess inhibit linear growth
probably as a result of their catabolic effects on bone, muscle and connective tissue
and inhibition of the effects of IGF-1. In bone, glucocorticoids inhibit osteoblast
function and IGF-1 generation, while osteoclast numbers increase; they also inhibit
the generation of matrix collagen and its mineralisation. Glucocorticoids inhibit
calcium absorption in the gut, while increasing renal calcium excretion by interfering
with vitamin D action. In muscle, glucocorticoids are associated with atrophy of type
II muscle fibres, and in connective tissue with reduced collagen synthesis.
Glucocorticoid treatment during pregnancy reduces birth weight in animals (Reinisch
et al 1978, Ikegami et al 1997, Nyirenda et al 1998, Newnham et al 1999, Newnham
2001) and in humans (French et al 1999, Bloom et al 2001).
1.7.6.4 Effects on the brain
Glucocorticoids are essential for normal brain development and both GR and MR are
expressed in many parts of the brain including the hippocampus, hypothalamus,
cerebellum and cortex (McEwen et al 1986). Glucocorticoid excess can have a
number of adverse effects on cells in the CNS, particularly in the hippocampus.
These effects include disruption of synaptic plasticity, atrophy of dendritic processes
and, under some circumstances, cell death (Sapolsky 1999). In addition,
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glucocorticoid excess has a number of psychological effects including depression,
lethargy and psychosis.
1.7.6.5 Other effects
Glucocorticoids have many other important effects including anti-inflammatory
actions and immunomodulatory functions. Glucocorticoids also have effects on the
gut, and a number of other endocrine systems.
1.7.7 Glucocorticoids and obesity
Excess circulating glucocorticoids are associated with obesity, particularly
abdominal obesity. In Cushing's syndrome, exposure to elevated circulating
glucocorticoids results in the accumulation of visceral fat, cardiovascular
complications and a number of metabolic sequelae, including glucose intolerance,
insulin resistance, diabetes and hyperlipidaemia. Obesity in humans is associated
with a similar pattern of cardiovascular risk factors; a cluster of features termed the
'metabolic syndrome'. Additionally, increased Cortisol concentrations in blood,
saliva and urine are associated with hypertension, glucose intolerance, insulin
resistance and hyperlipidaemia (Phillips et al 1998, Phillips et al 2000).
Such findings have prompted a number of studies that have sought to determine
whether abnormalities in glucocorticoid secretion, action or metabolism may
underlie the development of visceral adiposity and the metabolic syndrome
associated with obesity. Much work to characterise alterations in glucocorticoid
metabolism associated with obesity has been carried out in animal models. Obese
Zucker rats, which are leptin resistant due to a homozygous point mutation in the
leptin receptor gene, have been used to explore the changes in glucocorticoid
metabolism associated with obesity. Obese Zucker rats are hypercorticosteronaemic,
hyperinsulinaemic, insulin resistant and have HPA axis activation (Livingstone et al
2000a, Mattsson et al 2003). Recent studies have shown that there are tissue-specific
alterations in glucocorticoid metabolism in these animals; in the liver, 11 (3-HSD 1 is
decreased, whereas 5a-reductase is increased, suggesting increased hepatic
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glucocorticoid inactivation. In contrast, in visceral adipose tissue, the activity of 11(3-
HSD 1 is increased, which may enhance local glucocorticoid reactivation and
promote obesity (Livingstone et al 2000a). Furthermore, decreased reactivation of
corticosterone by 11(3-HSD 1 in the hippocampus may exacerbate the HPA axis
activation (Mattsson et al 2003). In addition, a number of studies have demonstrated
altered peripheral and central GR and MR expression in the obese Zucker rat.
Recently it has been shown that MR expression is decreased in the hippocampus in
obese rats (Mattsson et al 2003). Mineralocorticoid receptors mediate glucocorticoid
feedback in the basal state, and this decrease in expression may further explain the
HPA activation observed in the obese animal. Other studies have demonstrated
changes in peripheral levels of GR, reporting normal or reduced hepatic GR number
and affinity (Shargill et al 1987, White & Martin 1990, Langley & York 1992).
In such animal studies, obesity and features of the metabolic syndrome appear to be
glucocorticoid dependent, adrenalectomy or treatment with glucocorticoid receptor
antagonists reverses the obese phenotype in obese ob/ob mice and obese Zucker rats
(Yukimura et al 1978, Shimomura et al 1987, Langley & York 1990).
In humans most studies suggest that peak plasma Cortisol levels are not elevated in
idiopathic obesity (Phillips et al 1998, Rosmond et al 1998, Rask et al 2001,
Reynolds et al 2001), although there is evidence for increased Cortisol secretion
(Marin et al 1992, Pasquali et al 2002). Altered peripheral glucocorticoid metabolism
has been demonstrated in human subjects, with enhanced inactivation by 5a-
reductase (Andrew et al 1998), impaired reactivation by hepatic 1 lp-HSD 1 (Rask et
al 2001, Rask et al 2002) and enhanced reactivation in adipose tissue (Rask et al
2001, Rask et al 2002, Lindsay et al 2003).
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1.8 Aims of this thesis
The aim of this thesis was to study the intergenerational effects of programming by
in utero exposure to excess glucocorticoid in the rat and to delineate potential
underlying mechanisms. We also sought to investigate whether the programming
phenotype was amplified by obesity. The following list of aims was addressed in this
thesis:
1. To study whether dexamethasone programming in rats is associated with any
effects on birth weight, PEPCK and glucose tolerance in subsequent generations
without any further manipulation.
2. To investigate the influence of maternal and paternal phenotypes on
intergenerational programming.
3. To develop a model of high fat feeding in which to study the effects of
obesity on the programming phenotype.










Other organic solvents BDH-Merck, Poole, Dorset, UK.
Hayman Ltd., Witham, Essex, UK.
Malate Dehydrogenase Roche Diagnostics Ltd., Lewes, East
Sussex, UK.
All other solid chemicals Sigma-Aldritch Ltd., Poole, Dorset, UK.
Enzymes were purchased from Promega, Southampton, UK.
HPLC grade solvents were obtained from Rathburn Chemicals, Walkerburn, UK.
Radioactivity was obtained from Amersham, Bucks, UK.
Sources other than these are indicated in parenthesis.
2.1.2 Molecular Biologicals
TaqMan™ primers and probes
TaqMan™ PCR core reagent kit Applied Biosystems, Applera,
Warrington, Cheshire, UK.
NICK sephadex G-50 DNA column Amersham Pharmacia Biotech, Little
Chalfont, Buckinghamshire, UK.




PicoFluor 40 Scintillant fluid
TRIzol®
Random Primed DNA Labeling Kit
Kodak Biomax MS film










Ultra-Turrax T8 auto-homogeniser Ika Labortechnik, Staufen, Germany
Dri-block DB Series Techne, Cambridge, Cambridgeshire,
UK
GeneQuant RNA/DNA Calculator Amersham Pharmacia, Biotech
1450 Microbeta Plus Liquid Scintillation Wallac Oy
Counter (used for standard cpm counting)
EppendorfCentrifuge 5415C Eppendorf AG, Hamburg, Germany
(used for <2ml volume Eppendorf tubes)
Labofuge 400R Centrifuge Heraeus, Brentwood, Essex, UK
(used for 15 and 50 ml volume Falcon and Corning tubes)














Microvette tubes (CB 300)
Electrophoresis Power Pac 300
Eppendorf Mastercycler gradient
(PCRs, RTs and RNA denaturation)
Shimadzu Europa, Milton Keynes,
Buckinghamshire, UK
Bio-Tek Instruments Inc, Winooski,
Vermont, USA
Raytest Scientific Ltd
Fuji Photo Film Company Ltd, Tokyo
Japan
TLC Aluminium sheets Merck,
Darmstadt, Germany













Fujifilm Fluorescent Image Analyser
FLA-2000 V.1.0









Raytest Scientific Ltd, Sheffield UK
Statsoft, Tulsa, Oklahoma, USA
dFEO, UV-treated and autoclaved
0.5ml DEPC was added to 500ml
deionised water, agitated and left to
stand for 1-24 hours before autoclaving.
8.25g boric acid and 2.7g Sodium
hydroxide were dissolved in 11 dFEO
and set to pH 7.4 with hydrochloric
acid.
150ml formamide was mixed with 15g
mixed bed ion-exchange resin for >1
hour, filtered twice and stored away
from light.
0.2M 3-[N-morpholino]propanesulfonic
acid, 50mM Na acetate, 5mM EDTA,
pH7. Autoclaved before use.
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Loading buffer for Northern Blot
Homogenisation buffer
C Buffer
104.9g TRIS, 55.7g boric acid and 4.7g
sodium EDTA were made up to 11 with
deionised water and autoclaved.
13.8g sodium dihydrogen phosphate
(0.2M), 42.6g disodium hydrogen
phosphate (0.6M), 0.93g EDTA were
made up to 500ml with deionised water
and autoclaved.
350.64g sodium chloride and 176.46g
sodium citrate were made up to 21 with
deionised water, set to pH 7.4 with
hydrochloric acid and autoclaved.
lOmM tris, ImM EDTA, adjusted to pH
8 with hydrochloric acid. Autoclaved
before use.
50% glycerol, ImM EDTA, 0.25%
Bromophenol blue, 0.25% xylene
cyanol.
lOOg glycerol solution, 300mg Tris,
186mg EDTA made up to 500ml with
dEBO, set to pH 7.5 and stored at 4°C.
Just prior to use 7.7mg DTT was added
to a 50 ml aliquot.
63g glycerol, 8.77g sodium chloride,
186mg EDTA, 3.03g Tris made up to




42.8g sucrose and 0.6g Hepes made up




42.8g sucrose and 1.2g Hepes made up
to 500ml with dH20 and set to pH 7.5.
Stored at 4°C.
5P-reductase assay buffer 10.95g sucrose (320mM) and 15.4mg
DTT (ImM) made up to 100 ml with
40mM sodium phosphate buffer set to
pH 7.4. Made up fresh prior to use.
Kreb's Ringer Bicarbonate Buffer 118mM NaCl, 3.8mM KC1, 1.19mM
KH2P04, 2.54mM CaCl2, 1.19mM
MgS04, 25mM NaHC03, pH 7.4.
Stored at 4°C and supplemented with
0.2% glucose immediately prior to use.
2.5 Animal maintenance
Wistar rats were supplied by Charles River UK Ltd, Margate, Kent, UK. Females
were purchased for mating at 200-250g, along with males of equivalent age.
Feed (Standard rat chow) was supplied by Special Diets Services, Witham, Essex,
UK, and contained 61.9% carbohydrate, 18.8% protein, 3.4% oil and 0.6% salt.
High fat and Control diets were supplied by Research Diets Ltd, New Brunswick,
New Jersey, USA. Contents are detailed in Section 2.20.
All animal procedures were carried out under the terms of the Animals (Scientific
Procedures) Act 1986 and Project Licence number 60/2466. William Mungall, Keith
Chalmers, Donald Hay and Sharon Rossiter were responsible for the maintenance of,
and prenatal treatment of rats. Animals were under the primary care of the animal
research technicians at the Biomedical Research Facility throughout the experimental
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period. All rats were maintained under conditions of controlled lighting (lights on
0700 to 1900 hours daily) and temperature (22°C), with ad libitum access to food
and water. Adult and post weaning rats were kept five to a cage except where
otherwise stated and cleaned out weekly.
2.5.7 Production and care of offspring
Rats were allowed to acclimatise for two weeks after arrival in the animal unit,
before mating, at which time a single virgin female was housed with a male in a
breeding cage. The day on which the expelled vaginal plug was noted was designated
day zero of pregnancy (E0); females were then housed singly throughout pregnancy
until delivery, which occurred on days 20 to 22. Litters were weighed individually at
birth and culled to eight, leaving males and females. Pups were weaned at three
weeks of age and housed with littermates or with same aged pups from the same
treatment group. In all cases experimental cohorts included males and females
selected randomly from as many litters as possible.
2.5.2 Prenatal administration of dexamethasone
Pregnant females were injected subcutaneously with a solution of lOOpg per kg
dexamethasone in 0.9% saline containing 4% ethanol (F1 dex mothers) or with an
equivalent volume of vehicle (1ml/kg) (F1 veh mothers) at the same time each
morning between days 15 and 21 ofpregnancy inclusive.
2.5.3 Culling and harvesting of tissues
Animals were killed by cervical dislocation, CO2 or decapitation, between 9am and
12pm, without prior withdrawal of food unless stated. Tissues were dissected,
weighed where appropriate and snap frozen on dry ice. Tissues were stored at -80°C.
Trunk blood was collected into plastic tubes containing 1ml lOOmM EDTA through
an EDTA coated funnel and placed on wet ice. These samples were centrifuged as
soon as possible at 200g for 10 minutes at 4°C and the supernatant plasma aliquotted
into Eppendorf tubes and stored at -20°C.
48
2.6 Glucose Tolerance Tests
Rats were fasted for 17 hours prior to oral glucose tolerance testing. Commencing at
9am, rats were weighed. The tails were nicked with a scalpel towards the distal end
and the basal blood sample was collected into a Microvette CB 300 tube with EDTA
(Sarstedt). 2g/kg glucose solution (0.5g/ml) was administered by gavage, and the rats
were replaced in their cages. Further samples were taken from the same tail nick by
massaging the tails at 30 and 120 minutes after administration of glucose.
Approximately 300pl blood was taken at each time point, and centrifuged as before
for collection of plasma, before storage at -20°C.
2.7 Measurement of plasma insulin and leptin concentrations
The concentration of insulin in plasma samples was measured using Crystal Chem®
rat insulin ELISA and ultrasensitive rat insulin ELISA kits (Crystal Chem Inc.,
Chicago, Illinois, USA) according to the manufacturer's instructions. The standard
kits measure insulin concentration in the range of 156 to lOOOOpg/ml; intra- and
inter-assay CVs are reported as 3.5 and 6.3%. The ultrasensitive rat insulin ELISA
kit measures insulin concentration in the range of 100 to 6400 pg/ml; intra- and inter-
assay CVs are reported as 5.5% and 4.8%. Leptin concentrations were measured in
trunk plasma using Crystal Chem® mouse leptin ELISA kit. The manufacturer
reports that the anti-mouse antibody cross reacts 90% with rat leptin. The mouse
leptin ELISA kit measures leptin concentration in the range of 200 to 12,800 pg/ml;
intra- and inter-assay CVs are reported as 5.4% and 6.9%.
2.8 Measurement of plasma glucose concentrations
This assay was performed on samples taken during oral glucose tolerance testing,
using the Sigma Infinity™ glucose reagent. Hexokinase catalyses the
phosphorylation of glucose to glucose-6-phosphate. The product is then oxidised to
6-phosphogluconate, with the generation ofNADH. The amount ofNADH formed is
proportional to the amount of glucose present, and was measured by the increase of
UV absorbance of the reaction mixture at 340nm. The UV absorbances of lOpl
plasma sample or glucose standard (0-44mmol/l) were then measured in duplicate in
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a single assay after the addition of 1500 jul reagent and 5-60 minutes incubation at
room temperature. Standard curves of [glucose] versus UV absorbance units were
used to calculate the glucose concentrations of the sample. The inter- and intra-assay
coefficients of variation were <2%.
2.9 Measurement of plasma lipid parameters
These measurements were made by Dr Philip Wenham, Department of Medical
Biochemistry, Western General Hospital, Edinburgh.
Automated assays based on a colourimetric end-point were used, utilising kits
obtained from Wako Pure Chemical Industries Ltd, Osaka, Japan (Non-Esterified
Fatty Acids) or Roche Diagnostics Ltd (Total and High Density Lipoprotein
Cholesterol and Triglycerides).
2.10 Measurement of plasma corticosterone concentration
Plasma corticosterone concentration was measured by radioimmunoassay. The assay
was developed by Dr Chris Kenyon, who reported intra- and inter-assay variations of
9.4 and 9.2% respectively, and cross-reactivities for progesterone,
deoxycorticosterone and Cortisol of 7.7, 6.5 and 5.3% respectively, compared to
corticosterone (100%).
Plasma was diluted 1:10 in borate buffer containing 0.5% BSA, and heated to 75-
80°C for 30 minutes to destroy corticosterone-binding globulin.
3H-corticosterone was suspended in borate buffer to give between 10000 and
15000cpm per 50pl solution on the P-counter. Rabbit anti-corticosterone antibody
was added to this mix in a 1 TOO dilution.
20pl aliquots of diluted plasma sample or corticosterone standard (320, 160, 80, 40,
20, 10, 5, 2.5, 1.25, 0.625 and OnM corticosterone in borate buffer) were incubated in
duplicate with 50pl 3H-corticosterone/primary antibody mix in 96 well plates.
50pl scintillation proximity assay beads (SPA; Amersham, Bucks, UK) diluted with
borate buffer was then added to each well, the plates were then sealed, shaken and
left at room temperature overnight (<24 hours) to equilibrate. Plates were counted on
the P-counter and the concentration of corticosterone in each sample was calculated
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from a graph of cpm versus [corticosterone] generated using the Multicalc
programme.
2.11 Measurement of blood pressure by carotid cannulation
These measurements were performed by Dr Patrick Hadoke of the Department of
Endocrinology. Briefly, cannulae were placed in a carotid artery under anaesthesia,
flushed with 0.2ml heparin (20 units/ml), and the animal allowed to recover for 12-
24 hours. On the day following surgery (day 1), the cannula was flushed with 0.2
units heparin. Blood pressure was measured on days 2 and 3 (cannulae were almost
always found to be blocked by day 4), after connecting the cannula to a pressure
transducer. Blood pressure was measured with the animal in a quiescent state and
unrestrained, over a period of 5 minutes.
2.12 Extraction of total RNAfrom tissue
2.12.1 Liver
RNA was extracted with TRIzol®, using a method derived from that of
Chomczynski & Sacchi (Chomczynski & Sacchi 1987). Approximately lOOmg of
liver was homogenised in 1 ml TRIzol®. The mixture was allowed to stand for 5
minutes at room temperature to permit the dissociation of nucleoprotein complexes.
200pl of chloroform per 1 ml of TRIzol® was added and the tubes shaken for 15
seconds. The tubes were centrifuged at 14000g at 4°C for 15 minutes and the upper
aqueous phase transferred to another Eppendorf. 0.5ml propan-2-ol per 1ml TRIzol®
was added and the mixture vortexed. The tubes were incubated at room temperature
for 10 minutes to precipitate the RNA and then spun at 14000g for a further 10
minutes to pellet the RNA. The supernatant was discarded and the pellet washed by
vortexing with > 1 volume 75% ethanol. The tubes were then centrifuged at 7500g
for 5 minutes at 4°C. The ethanol was removed by drawn-out pasteur pipette and the
pellet air-dried before resuspending in DEPC-treated water. Resuspended RNA from
the same tissue sample was recombined in a single tube.
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2.12.2. Adipose tissue (except omental adipose tissue)
As for liver, except that the tissue was first homogenised in TRIzol®, involving an
average of three 10 second bursts at the three-quarter speed setting, and centrifuged
at 2000g for 3 minutes at 4°C. The upper lipid layer was discarded, and the subnatant
aliquotted into Eppendorf tubes for RNA extraction.
2.12.3 Omental adipose tissue
Only small amounts of omental adipose tissue were available for RNA extraction,
therefore the RNAID matrix (Anachem, Luton, UK) was used. This effectively binds
RNA, sequestering it away from possible RNAse degradation. Using this system,
RNA can be eluted in high concentrations and purity with washes that remove
impurities without loss of bound RNA. Following homogenisation in TRIzol®, and
separation from the upper lipid layer as described above, RNA was extracted as
follows. 250pl of chloroform was added, samples were vortexed, incubated at room
temperature for 2 minutes then on ice for 15 minutes. Samples were then centrifuged
at 12000g for 15 minutes at 4°C. The upper aqueous phase was transferred to another
Eppendorf. To this was added 20pl of resuspended RNAID Matrix, followed by
vortexing. Samples were spun at 14000g for 1 minute. The supernatant was removed
and discarded. The pellet was washed with 500pl wash buffer (RNA wash;
Anachem) followed by centrifugation at 14000g to produce a pellet. After repeating
the wash step twice more, the wash buffer was removed and the pellet resuspended in
18ja.l DEPC- treated water with RNase inhibitor and DTT (89pl DEPC- water, lOpl
lOOmM DTT, lpl RNase inhibitor).
2.13 Quantitation and agarose gel electrophoresis of
extracted RNA
lpl of resuspended RNA from each sample was diluted with 99pl DEPC-treated
water and its UV absorbance at 260 and 280nm measured on the GeneQuant. The
RNA concentration in the sample was calculated from this. The ratio of Absorbance
(260nm) / Absorbance (280nm) was also recorded as an indication of the purity of
the RNA. Values close to 2.0 are desirable.
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Agarose gel electrophoresis was used to ensure that the RNA was intact. A 30ml 1%
agarose gel was used containing 3ml lOx TBE and 0.5pi ethidium bromide using
RNase-free materials. 0.5-1.0pg of RNA was loaded in 2.5pl loading buffer per
sample, and electrophoresis performed in 0.5 x TBE. The gel was run at 60mA for
approximately 40 minutes and the results viewed on the trans-illuminator at 240nm.
The presence of intact 28S, 18S and 5S Ribosomal RNA bands indicated that the
preparation was undegraded.
2.14 Protein concentration
Protein concentration of tissue homogenates and microsomal preparations was
determined colorimetrically using a Bio-Rad protein assay kit (Bio-Rad, Hemel
Hampstead, UK). Samples were diluted with buffer to give solutions in the linear
range of 0.05-1.4 mg protein/ml, and BSA standards were prepared in the same
buffer to 0.05, 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2, 1.4 mg/ml. 25pl BIO-RAD protein
assay solution A and 200pl BIO-RAD protein assay solution B were added to
duplicate lOpl aliquots of samples and standards in a 96 well plate. After 15 minutes
incubation at room temperature, the absorbance in each well was measured at 750nm
in a microplate reader. The concentration of protein in each sample was calculated
from the mean absorbance, the dilution factor, and a graph of [protein standard]
versus mean absorbance at 750nm.
2.15 PEPCK assay
PEPCK catalyses the decarboxylation and phosphorylation of oxaloacetate to form
phosphenolpyruvate during gluconeogenesis. It also catalyses the reverse reaction
(incorporation of carbon dioxide and dephosphorylation, with dGDP as the
phosphate acceptor). The assay measures PEPCK activity by coupling oxaloacetate
formation with its reduction by excess malate dehydrogenase to yield malate, with
the equimolar consumption of NADH. The rate of the decrease in NADH
concentration can be measured spectrophotometrically and is directly proportional to
the activity of the PEPCK in a sample (Petrescu et al 1979).
Portions of liver from freshly killed rats were collected into Eppendorf tubes and
1.25ml ice-cold 250mM sucrose/ 5mM HEPES buffer pH 7.4 was added. The
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samples were homogenised at 4°C and centrifuged at 12000g for 15 minutes at 4°C.
The cytosolic supernatant was removed into ultracentrifuge tubes and spun for 45
minutes at 60000g at 4°C. The supernatant was removed into Eppendorf tubes and
kept on ice. The appropriate amount of sample (20-60pl) was incubated at 30°C for 3
minutes in a reaction mixture containing: 50pl NADH (3.6mg/ml), 40pl
phosphoenolpyruvate (10.4mg/ml), 50pl malate dehydrogenase (1.5iu, Roche
Diagnostics Ltd, Lewes, UK) and made up to 1ml with buffer (50mM HEPES pH
6.5, 50mM sodium bicarbonate and ImM manganese (II) chloride). The reactions
were initiated in a spectrophotometer (set to 'Kinetic' mode) using 0.15mM dGDP.
The drop in absorbance at 340nm was followed for three to seven minutes. Reaction
mixtures lacking bicarbonate were used as negative controls. PEPCK activity was
calculated from the rate of decrease in absorbance during the linear phase of the
curve, and the molar absorptivity ofNADH.
2.16 Northern blotting
2.16.1 RNA electrophoresis and capillary transfer
Total RNA was separated by electrophoresis on a 1.2% agarose formaldehyde
denaturing gel. A 500ml gel was prepared by melting 6g of agarose in 440ml DEPC-
treated water, adding 10ml formaldehyde and lOx MOPS buffer (50ml), and pouring
into a gel mould with appropriately sized combs in place. The gel was allowed to set
and was then pre-run in lx MOPS buffer in a gel tank for 15 min at 80V. RNA was
prepared for electrophoresis by aliquoting 20pg ofRNA, adding DEPC-treated water
to bring the total volume to 10pl, then adding deionised formamide (lOpl), 40%
formaldehyde (2.5pl) and lOx MOPS buffer (2.5pl) to give a total volume of 25pl.
The sample was mixed and the RNA denatured by incubating at 65°C for 15min.
Ethidium bromide was added to the loading buffer (lpl per 50pl loading buffer) and
2pl of this mix added to each sample of denatured RNA. The RNA was loaded into
the wells on the gel and electrophoresed at 100V for 2 - 4 hours until the front band
of the loading buffer was % of the way down the gel. The gel was photographed
under UV light (A,=254nm) with as little exposure as possible to minimise RNA
damage. The gel was soaked in 20x SSC buffer for 15min before blotting onto a
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nylon membrane (Zeta-Probe®). A wick of Whatman 3MM filter paper was placed
over an upturned gel mould in a plastic tray containing 20x SSC buffer and the gel
was placed on the top. A piece of nylon membrane cut to the same size as the gel
and pre-wetted in 20x SSC was smoothed on top of the gel and this was covered with
3 layers of 3MM filter paper and approximately 5cm of paper towels. A plate of
glass was placed on the top to secure the apparatus, and a weight balanced on the top.
Capillary transfer was allowed to take place overnight at room temperature. The
next day the membrane was washed in 20x SSC to remove any gel and the efficiency
of transfer was checked by photographing the gel and the membrane under UV light
(A=254nm). The membrane was dried between two sheets of 3MM filter paper at
80°C for 2 hours, and the RNA cross-linked under UV light.
2.16.2 Hybridisation to 32P-labelled cDNA
The nylon membrane was soaked in 20x SSC buffer for 5min, then placed in Hybaid
hybridisation bottle containing 3ml 20% SDS and 6ml phosphate buffer that had
been warmed to 55°C. To this was added denatured salmon sperm DNA (lOmg/ml;
125jul). The membrane was prehybridised in a Hybaid hybridisation oven at 55°C
for at least 2 hours. The 32P-labelled cDNA probe (prepared as described in section
2.17.3) was added to the prehybridisation buffer, and the membrane hybridised with
the probe overnight at 55°C. The probe was disposed of and the membrane was
washed as follows: two washes in lxSSC: 0.1%SDS at 55°C for 20min, and one
wash in 0.3xSSC: 0.1%SDS at 55°C for 20min. The membrane was wrapped in
cling-film and exposed to a Fujifilm imaging screen overnight for all probes (except
Ul, which was exposed for 10-15 minutes) and the level of hybridized probe
quantified using a Fuji FLA2000 fluorescent image analyzer. The membranes were
then rehybridised with Ul cDNA in the same way to control for RNA loading and
transfer. The level of expression of the RNA of interest was then expressed as a ratio
of the signal of the RNA of interest to the signal for Ul. If results between groups of
animals were to be compared all the samples were hybridised in the same
hybridisation bottle with the same probe.
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2.16.3 [32P] Labelling of cDNA
DNA fragments were a kind gift from Dr D Livingstone. A random primed DNA
labelling kit was used to label the DNA fragments (Roche Diagnostics Ltd UK).
Approximately 25ng of DNA fragment was aliquoted into an Eppendorf, made up to
lOpl with DEPC-treated water and denatured at 100°C for lOmin. The Eppendorf
was cooled on ice and briefly centrifuged to bring the contents to the bottom of the
Eppendorf. Hexanucleotide primer mix (2pl), dATP, dTTP and dGTP (lpl of each),
[a32P]-dCTP (4pl) and Klenow (lpl) were added to give a total reaction volume of
20pl and the reaction incubated at 37°C for one hour. Unincorporated radioactivity
was removed by passing the mixture over a NICK column (Pharmacia, St.Albans,
UK). The NICK column was prepared by washing with 3ml TE then the reaction
mixture was applied to the column. The column was washed with 400pl TE, the
eluant discarded and the labelled DNA eluted from the column with a further 400pl
TE. The activity of the probe was checked by mixing 2pl of probe with 1ml of
scintillant and counting in a P-counter. The probe was used if the specific activity
was greater than 70,000cpm/pL The DNA probe was denatured before use by
heating to 100°C for 5min.
2.17 11P-HSD 1 assay
In vivo, lip-HSDl is a reductase, converting inactive 11-dehydrocorticosterone to
corticosterone. However, in vitro, reductase activity is labile and dehydrogenase
activity predominates in tissue homogenates, so lip-HSDl activity was quantified
by conversion of corticosterone to 11 -dehydrocorticosterone.
Preliminary studies were carried out for each different tissue to optimise the protein
concentration and incubation time to ensure that the percentage conversion was
between 10 and 40% (ie not saturated).
2.77.7 Method 1
Aliquots of tissue homogenates at the appropriate concentration were incubated in
duplicate at 37°C in C buffer containing [3H]-corticosterone (lOnM), NADP
(400pM), for the times indicated in table 2.1. Blanks were prepared by incubating
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[3H]-corticosterone, NADP and C buffer with no tissue added. The reaction was
stopped and steroids extracted by the addition of ethyl acetate. The organic phase
was removed and evaporated. Extracts were resuspended in 3 5pi of a solution of
corticosterone and 11 -dehydrocorticosterone (0.5mg/ml in 100% ethanol) and
analysed by thin layer chromatography using a mobile phase of 92% chloroform and
8% methanol.
2.17.2 Method 2
Aliquots of tissue homogenates at the appropriate concentration were incubated in
duplicate at 37°C in Kreb's Ringer bicarbonate buffer containing 0.2% glucose,
NADP (2 mM) and [3H]-corticosterone (50 nM) in a total volume of 250pl, for the
times indicated in table 2.1. Blanks were prepared by incubating [3H]-corticosterone,
NADP and buffer with no tissue added. After the incubation period the reaction was
stopped by the addition of 10 volumes of ethyl acetate (all solvents used were HPLC
grade). The organic phase was removed and evaporated under oxygen free nitrogen
at 60°C. Extracts were re-suspended in mobile phase (20% methanol, 30%
acetonitrile and 50% water) and stored at -20°C until analysis by HPLC. The
percentage of [3H]-B converted to [3H]-A was corrected for apparent conversion in
the blank samples, which was always <3%, and was used as an index of 11J3-HSD 1
activity. Where results between different groups of animals were to be compared all
the incubations were carried out concurrently, and all samples treated in the same
way.
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Tissue Protein Incubation period Method
concentration
Liver
3 week/20 week 0.2mg/ml 15 min 1
24/72 hour 50pg/ml 1 hour 2
Subcutaneous fat
3 week 0.5mg/ml 3 hours 1
20 week 0.4mg/ml 6 hours 1
24/72 hour 500pg/ml 2 hours 2
Omental fat
3 week/20 week 0.5mg/ml 3 hours 1
24/72 hour 250pg/ml 2 hours 2
Table 2.1 Incubation times, protein concentrations and methods used for 1 lp-HSD 1
assay on tissues from Wistar rats on high fat or control diets. 3 weeks, 20 weeks and
24/72 hours refer to length of time on high fat and control diets as described in
chapter five.
2.18 5(3- Reductase assay
lOOmg of liver was homogenised in sucrose buffer (0.25M, pH7.5), HEPES (lOmM)
and dithiothreitol (ImM). Cytosolic and microsomal sub-fractions were separated by
differential centrifugation. Briefly, homogenised liver samples were centrifuged
(lOOOg 4°C, 10 min) and the supernatant removed and centrifuged (34,000g, 4°C, 30
min). The resulting supernatant was further centrifuged (124,000g, 4°C, 60 min),
yielding cytosolic supernatant for analysis. The protein concentration was
determined colorimetrically. Cytosolic preparations (400p,g/ml protein) were
incubated in duplicate at 37°C in potassium phosphate buffer 0.1M, pH 7.5
containing glucose-6-phosphate (5mM), glucose-6-phosphate dehydrogenase (0.1
units/ml), NADPH (2mM), [3H] corticosterone (50nM) and unlabelled corticosterone
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(9.95pM). After 2 hours, steroids were extracted with ethyl acetate, dried down and
resuspended in mobile phase (water:acetonitrile:methanol; 60:10:30). Steroids were
separated by HPLC, and their concentrations quantified by on-line scintillation
counting. 5P-reductase activity was expressed as % conversion of [3H] corticosterone
to [3H] 5P-tetrahydrocorticosterone (5P-THB).
2.19 Real-Time PCR
Real-time polymerase chain reaction (PCR) was performed to quantify mRNA for
11P-HSD 1, GR and 5a-reductase in liver and fat.
2.19.1 Preparation of cDNA
RNA was extracted from tissues as described in section 2.13. cDNA was synthesised
from 0.5pg RNA samples using the Promega Reverse Transcription System
(Promega, Southampton, Hants, UK) in a reaction mixture containing 25mM MgCh,
lOx reverse transcription buffer, lOmM each of dATP, dCTP, dGTP and dTTP, 20U
RNasin, 0.5pg 01igo(dT)i5 primers and 15U AMV-reverse transcriptase made up to
50pl in DEPC-treated water. Samples were incubated at 42°C for 50 min followed
by 5 min at 99°C then 5 min on ice to inactivate enzymes and prevent binding to
DNA.
Negative control reactions for each RNA sample were performed in parallel (made
up as above but in the absence of AMV-reverse transcriptase) in order to exclude
genomic DNA contamination. A further negative control reaction containing water
instead of RNA was performed to determine RNA contamination of the Reverse
Transcriptase System reagents.
PCR amplification was performed on a third to one half of the cDNA samples to
confirm successful reverse transcription as described in section 2.20.2, using
Glyceraldehyde 3-phosphate dehydrogenase primers (table 2.2). CDNA was diluted
1:4, aliquotted and stored at -20°C until use.
PCR amplification of samples using the Real Time PCR primers and probes for lip-
HSD 1, GR and cyclophilin showed amplification ofproducts of the appropriate size.
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2.19.2 PCR reactions
5pl of cDNA template was used in each PCR reaction containing 2.5pl of lOx
Thermophilic DNA polymerase Reaction Buffer containing 25mM MgCh and made
up to a final volume of 25pi with DEPC-treated water. A second mixture containing
2.5pl of lOx Thermophilic DNA polymerase Reaction Buffer containing 25mM
MgCl2, 2.5mM each of dATP, dCTP, dGTP and dTTP, 15pmol upstream primer, and
15pmol downstream primer was made up to 25pl in DEPC-treated water. 0.25pl of
Taq polymerase was added to each reaction tube just prior to starting the required
PCR programme. A negative control reaction containing DEPC-treated water rather
than cDNA was performed in parallel to determine contamination ofPCR reagents.
PCRs were performed on an Eppendorf Mastercycler Gradient with a heated lid (set
to 110°C). Samples were heated to 95°C for 3min for initial denaturation, placed
directly on ice for lmin before the addition of the second mixture. All samples then
underwent 35 cycles of PCR amplification (denaturation at 94°C for lmin, primer
annealing at primer-specific temperature for 1 min and elongation at 72°C for 2 min).
Upon completion of the PCR programme, samples were incubated at 72°C for a
further 10 min to ensure elongation of products to full length and cooled to 4°C prior
to gel electrophoresis.
RT-PCR products were analysed by electrophoresis on a 1.0% agarose gel using
10pl 1Kb DNA ladder containing fragments ranging from 75-12,000 bases to allow
determination of product size.
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Mouse Accession Amplicon Tm cDNA
Sequence (5'-3')
positionGAPDH number length (°C)
FP gtcggtgtgaacggatttggccgt M32599 1001 56 51-79
RP catggcctacatggcctccaagg 1021-1043
Table 2.2 PCR primer sequences for GAPDH.
FP= forward primer, RP= reverse primer. Annealing temperature = 56°C; 35 cycles
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Table 2.3 Real Time PCR primers and probe sequences, amplicon lengths and
cDNA position. 5a-R 1 = 5a-reductase type 1. Annealing temperatures: cyclophilin
59°C, lip-HSD 1 52°C, 5a-reductase 59°C. FP= forward primer, RP= reverse
primer.
62
2.19.3 Real-time PCR probes and Primers
Exon-spanning probes and primers were designed using Primer Express software
(Applied Biosystems, Warrington, UK) and are detailed in table 2.3. Cyclophilin was
chosen as the endogenous control.
GR, lip-HSD 1 and 5a-reductase probes were labelled with the fluorescent dye
FAM, and cyclophilin with the fluorescent dye VIC.
Reactions were carried out on 384 well plates using a final volume of lOpl per well.
A master TaqMan mix was made, consisting of (per well) 300nM forward and
reverse primers, 200nM probe, 2.5pl cDNA, 6.86pl TaqMan Universal PCR Master
Mix (Applied Biosystems, Applera, Warrington, UK). Samples were run in triplicate
where possible, or otherwise in duplicate. Four wells per gene of interest were used
for a -RT sample generated during the RT-PCR, and two wells for a 'no template
control' reaction using nuclease-ffee water in place of cDNA.
A preliminary experiment demonstrated that 300nM both forward and reverse
primers and 200nM probe gave good amplification plots.
cDNA from the tissue of interest was pooled prior to dilution to use for the
generation of a standard curve. This stock cDNA was used in dilutions of 1, 1:2, 1:4,
1:8, 1:16, 1:32 and run in triplicate to generate a standard curve for relative
quantification of the target mRNA in samples.
Plates were analysed on a TaqMan™ ABI Prism 7900 Sequence Detector™. Cycling
parameters: 50°C for 2 mins, 95° for 10 mins, 40 cycles of 95°C for 15 sees, 60°C
for 1 min. Data acquisition was processed with Sequence Detector 1.6.3 software.
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2.20 Diet constituents
Diets were supplied by Research Diets, New Brunswick, New Jersey
Control diet High fat diet
D01072401 D12451
(g) kcal% (g) kcal%
Composition
Protein 19.2 20 23.7 20
Carbohydrate 67.3 70 41.4 35
Fat 4.3 10 23.6 45
Total 90.8 100 88.7 100
Kcal/g 3.85 4.73
Ingredients (g) kcal (g) kcal
Casein 200 800 200 800
L-Cystine 3 12 3 12
Corn starch 452 1809 72.8 291
Maltodextrin 10 75 300 100 400
Sucrose 172.8 691 172.8 691
Cellulose 50 0 50 0
Soybean oil 25 225 25 225
Lard 20 180 177.5 1598
Mineral mix SI0026 10 0 10 0
DiCalcium Phos 13 0 13 0
Calcium Carbonate 5.5 0 5.5 0
Potassium Citrate 16.5 0 16.5 0
Vitamin mix VI0001 10 40 10 40
Choline Bitartrate 2 0 2 0
Total 1055 4057 858 4057
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2.21 Statistics
All values are expressed as mean ± standard error. Data were statistically analysed
by Student's t tests or Analysis ofVariance followed by post-hoc LSD testing.
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Chapter Three - Intergenerational effects of glucocorticoid
programming in the rat
3.1 Introduction
As discussed in the introduction, many epidemiological studies have demonstrated a
link between low birth weight and a number of cardiovascular risk factors (Barker
1998). Evidence from human studies suggests that this phenomenon may not be
limited to the first generation and that intergenerational effects may operate, resulting
in the persistence of programming effects in subsequent generations.
Epidemiological studies in humans suggest that there may be intergenerational
effects on birth weight (Ounsted & Ounsted 1968, Klebanoff et al 1984, Carr-Hill et
al 1987, Klebanoff et al 1989, Emanuel et al 1992, Klebanoff et al 1997, Emanuel et
al 1999), cardiovascular risk factors (Davey Smith et al 1997, Walker et al 1998,
Lawlor et al 2002, Kuznetsova et al 2003) and type 2 diabetes (Alcolado & Alcolado
1991, Klein et al 1996, Karter et al 1999, Dabelea et al 2000).
Intergenerational effects have been explored in animal models; in utero exposure to a
low protein diet has intergenerational effects on birth weight and the endocrine
pancreas (Stewart et al 1975, Stewart et al 1980, Hoet & Hanson 1999, Martin et al
2000); postnatal dietary manipulations have been shown to have second generation
effects on glucose homeostasis (Laychock et al 1995, Vadlamudi et al 1995, Patel et
al 2001, Srinivasan et al 2003); and postnatal environmental manipulations may have
intergenerational effects on the HPA axis (Francis et al 1999).
One proposed mechanism for fetal programming is that of overexposure of the fetus
to glucocorticoids (Edwards et al 1993). Rats exposed to dexamethasone (dex)
during the last third of pregnancy are of low birth weight and develop hypertension
(Benediktsson et al 1993), glucose intolerance (Nyirenda et al 1998) and HPA axis
activation (Levitt et al 1996, Welberg et al 2001) in adulthood. The glucose
intolerance is thought, at least in part, to be mediated by increased activity of the
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hepatic gluconeogenic enzyme phosphoenolpyruvate carboxykinase (PEPCK)
(Nyirenda et al 1998).
Using this model of programming, we have explored intergenerational effects on
birth weight, hepatic PEPCK, glucose tolerance and blood pressure.
3.2 Methods
Female Wistar rats weighing around 250g were timed-mated with Wistar males and
then caged separately throughout gestation. Pregnant females were injected
subcutaneously with a solution of dexamethasone in 0.9% saline containing 4%
ethanol (lOOpg per kg body weight), or with an equivalent volume of vehicle
(1ml/kg), at the same time each morning between days 15 and 21 of pregnancy
inclusive (n=8 per group).
Litters (F1 dex and F1 veh) were weighed at birth and culled to eight pups (n=8 dex
litters, 7 veh litters). Pups were weaned at three weeks of age and housed with
littermates or with same aged pups from the same treatment group. F1 females
weighing around 230-250g were timed-mated with F1 males from different litters of
the same prenatal treatment group (n=10 per group). Females were caged separately
during pregnancy and not manipulated in any way. Pups (F2 dex and F2 veh) were
weighed at birth and culled to eight (n=9 litters for both groups). Pups were weaned
at 3 weeks.
F2 females were timed-mated with unrelated males from the same F2 group (n= 10
per group). 10 litters were obtained for the dex group (F3 dex) and 9 for the veh
group (F3 veh). Pups were weighed at birth and each litter culled to eight.
All offspring were weighed at weaning and monthly thereafter. In all cases,
experimental cohorts included males and females selected randomly from as many
litters as possible.
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At 12 weeks (F1 and F3) or five weeks (F2) of age, male animals (n=8-10) from each
group were culled by cervical dislocation. Portions of liver were collected into
Eppendorfs and placed on wet ice for PEPCK analysis. The elevation in hepatic
PEPCK activity in dex animals has previously been shown to be stable between 21
days and 8 months of age (Nyirenda et al 1998).
Glucose tolerance tests were conducted on F1 males and females at 6 months of age,
on F2 animals at 4 and 6 months of age, and on F3 animals at 6 and 15 months.
Plasma glucose was determined by the enzymatic (hexokinase) method, and plasma
insulin by ELISA.
Corticosterone levels were measured by radioimmunoassay on tail nick plasma
samples taken between 0800 and 0900 hours following daily handling of the animals
for 10 days to 2 weeks.
Blood pressure was measured in animals at rest at the same time each day following
carotid cannulation by Dr Patrick Hadoke, Endocrinology Unit, University of
Edinburgh.
Data are expressed as mean ± SEM unless otherwise stated. Data were analysed
using unpaired t tests, 2-way or repeated measures ANOVA (glucose tolerance tests,





The F1 offspring of dex-treated mothers (F1 dex, n=74) were significantly lighter
than the F1 offspring of veh-treated mothers (F1 veh, n=81) (Figure 3.1), in
agreement with previous studies (Levitt et al 1996, Nyirenda et al 1998, Cleasby et al
2003a). There were no changes in gestation length, litter number or proportions of
male and female offspring (Table 3.1). Females receiving dexamethasone during the
last week of pregnancy gained less weight than those receiving vehicle injections,
consistent with previous reports (Table 3.1). Hepatic PEPCK activity tended to be
elevated in the liver of male F1 dex offspring (Figure 3.2). Although this result did
not reach significance, mean values are consistent with those from previous studies
(Nyirenda et al 1998).
Growth trajectories for male and female animals are shown in figure 3.3. Although
F1 dex males achieved catch-up growth by weaning at 21 days and thereafter
maintained equivalent weights to their F1 veh counterparts, F1 dex females never
achieved full catch-up growth. Thus, F1 dex females were lighter than F1 veh
females at the time ofmating.
There were no differences between F1 dex and F1 veh animals in glucose tolerance
(Figures 3.4 and 3.5), basal corticosterone levels (Table 3.1) or blood pressure (Table
3.1). Basal corticosterone levels in females were significantly higher than those in
males, in accordance with previous studies (Atkinson & Waddell 1997).
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F1 dex F1 veh P value
Gestation length
(days) 20.8 + 0.3 20.9 ±0.1 0.73
Litter number 11.5 ±0.8 12.7 ± 0.7 0.28
Maternal weight gain (g) 25.6 ±3.2 57.2 ± 3.7 <0.001
Basalplasma corticosterone (nmol/l) at 9 months
Males 30 ± 3 25 ± 3 0.37
Females 517 ± 100 661 ± 150 0.4
Mean bloodpressure (mmHg) at 14 months
Males 132 132 ±2
Females 115 ± 6 115 ± 7 0.94
Table 3.1 F1 cohort data for 8 dex litters and 7 veh litters.
Data are mean ± SEM and were analysed by Student's t test.
Corticosterone levels were measured in 6 veh males and 9 dex males and in 8
females per group.
Blood pressure was measured in 5 F1 veh and 6 F1 dex females, but because of
technical problems, only in four F1 veh and two F1 dex males.
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3.3.2 F2 cohort
Birth weight was reduced in the F2 dex offspring when compared with the F2 veh
offspring, although both groups were heavier than their F1 counterparts (Figure 3.1).
Although the F1 dex mothers were lighter than the F1 veh mothers at gestational day
EO (Table 3.2), there was no difference in maternal weight gain during pregnancy
(Table 3.2), in litter number, or in the proportions of male and female offspring
(Table 3.2). Hepatic PEPCK activity was elevated in the livers of male F2 dex
animals (Figure 3.2). F2 dex males and females both achieved catch-up growth by
weaning (Figure 3.3).
In previous F1 cohorts, glucose intolerance has not been noted before 6 months of
age (Dr Moffat Nyirenda, unpublished observations). However, in view of the
marked difference in PEPCK activity in this F2 cohort, glucose tolerance tests were
performed at 4 months as well as 6 months on F2 males and females. At 4 months
there were no differences in plasma insulin in the males (Figure 3.4) or in glucose or
insulin in the females during glucose tolerance testing (Figure 3.5). However, the F2
dex males had higher glucose values during the glucose tolerance test (Figure 3.4).
At 6 months, F2 dex males demonstrated higher basal insulin levels and an elevated
basal insulimglucose ratio (Table 3.2). Although F2 dex females did not demonstrate
overt glucose intolerance or insulin resistance at 6 months, there was a trend towards
an elevated basal insulin: glucose ratio (Table 3.2).
There were no differences in basal corticosterone levels (Table 3.2) in males or
females. F2 dex males had significantly elevated mean and systolic blood pressures
when measured by carotid cannulation at 13 months of age (Table 3.2). In contrast,
there was no difference in blood pressure in F2 females when measured at 17 months
(Table 3.2).
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F2 dex F2 veh P value
Litter number 11.6 ± 0.9 12 ± 0.6 0.68
Maternal weight at 241.8 ±4.3 259.4 ±3.2 0.005
E0 (g)
Maternal weight gain (g) 100.4 ±6.4 104.5 ±5.2 0.63
Plasma corticosterone (nmol/l) at 12 months
Males 180 ±37 202 ±31 0.65
Females 274 ± 96 379 ±81 0.42
Mean bloodpressure (mmHg)
Males (13 months) 137 ±3 128 ± 3 0.037
Females (17 months) 131 ± 3 125 ±4 0.21
Systolic bloodpressure (mmHg)
Males (13 months) 150 ±2 141 ± 3 0.03
Females (17 months) 142 ±3 135 ±4 0.24
Basal insulin (ng/ml) at 6 months
Males 1.08 ±0.05 0.92 ± 0.04 0.036
Females 0.25 ± 0.02 0.21 ±0.02 0.18
Basal insulin:glucose ratio (6 months)
Males 0.20 ±0.09 0.17 ±0.08 0.009
Females 0.050 ± 0.005 0.036 ± 0.004 0.057
Table 3.2 F2 data.
Data are for 9 litters per group. E0 = day when vaginal plug noted. Basal
corticosterone levels, n=8 per group. Mean and systolic blood pressures measured by
carotid cannulation (n=9 F2 veh males and 10 F2 dex males; n=8 F2 dex females and
6 F2 veh females). Basal insulin and insulin: glucose ratios for 9 F2 dex males and 8
F2 veh males; 10 F2 females per group.
Data are mean ± SEM and were analysed by Student's t test.
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Figure 3.1 Birth weights in F1 and F2 animals.
Birth weights in F1 (panel A n= 81 veh, n=74 dex) and F2 (panel B
n=108 veh, n=101 dex) animals.
Data were analysed by Student's t test * denotes p<0.05.
73
Figure 3.2 Hepatic PEPCK activity in F1 and F2 males.
PEPCK activity in F1 males at 12 weeks of age (panel A, p=0.097) and
F2 males at 5 weeks of age (Panel B), n=8 per group.
Data were analysed by Student's t test * denotes p<0.05.
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Figure 3.3 Weight trajectories F1 and F2 cohort.
Weight gain in F1 males (panel A, n=20-30 per group) and females (panel B,
n=10-13 per group).
Continuing weights in F2 males (panel C, n= 68 per group at 1 month, 29 at
months 2-3 and 24 at 4 months) and females (panel D, n=30 per group at 1-3




Figure 3.4 Glucose and insulin in F1 and F2 males on glucose tolerance testing.
Plasma glucose (panel A) and insulin (panel B) in F1 males at 6 months (n=10
per group).
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Figure 3.5 Glucose and insulin in F1 and F2 females on glucose tolerance testing.
Plasma glucose (panel A) and insulin (panel B) in F1 females at 6 months (n=10 per
group). Plasma glucose (panel C) and insulin (panel D) in F2 females at 4 months
(n=T0 per group).





There were no differences in birth weight between F3 dex and F3 veh litters (Table
3.3) or in hepatic PEPCK activity in male offspring (Table 3.3). There were no
differences between maternal weights at gestation EO, litter number, gestation length,
proportions of male and female offspring (Table 3.3) or in the postnatal growth
trajectories of F3 dex and F3 veh males and females.
Glucose tolerance testing was performed in males and females at 6 and 15 months of
age; no differences between dex and veh animals were found in glucose values for
males or females at either time point (Figure 3.6).







Maternal weight gain (g)
PEPCK activity
(nmol/min/mg protein)
Table 3.3 F3 cohort data
Data are for 10 F3 dex and 9 F3 veh litters. EO = day when vaginal plug noted. Birth
weights are for 108 F3 veh and 107 F3 dex animals. PEPCK activity was measured
in 8 F3 veh and 7 F3 dex animals at 12 weeks of age.
Data are mean ± SEM and were analysed by Student's t test.
5.90 ±0.05 5.80 + 0.06 0.22
21.6 ±0.2 21.8 ±0.2 0.61
10.7 ±0.7 12.0 ±0.5 0.17
268 ±7.7 267 ±4.7 0.93
117.3 ±5.8 118.2 ±2.7 0.89





















































Figure 3.6 Glucose tolerance tests in F3 males and females at 6 and 15 months.
Plasma glucose (panel A) and insulin (panel B) in F3 males at 6 months. Plasma
glucose (panel C) and insulin (panel D) in F3 females at 6 months. Plasma glucose
in F3 males (panel E) and females (panel F) at 15 months.
Analysis of data by ANOVA revealed no significant differences between groups at
either time point (n=8 per group).
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3.4 Discussion
These data demonstrate intergenerational effects in the dexamethasone-programmed
rat. Rats exposed to dexamethasone in utero have reduced birth weight, elevated
hepatic PEPCK and abnormal glucose tolerance (Nyirenda et al 1998) and we show
for the first time that the offspring of these rats, without further manipulation also
exhibit these features. These effects are no longer evident in a third generation.
Consistent with previous reports, birth weight was reduced in rats exposed to
dexamethasone in utero during the last week of pregnancy (Levitt et al 1996,
Nyirenda et al 1998, Welberg et al 2001, Cleasby et al 2003a). Birth weight was
reduced by 9% in the F1 dex animals, in agreement with previous studies which have
reported reductions in birth weight of between 6 and 11% (Levitt et al 1996,
Nyirenda et al 1998, Welberg et al 2001). Maternal weight gain was also reduced in
the dexamethasone treated animals, but no effects were seen on gestation length,
litter size, or offspring viability in the F1 generation.
In the F1 generation, there was a trend for hepatic PEPCK activity to be elevated.
Treatment with dexamethasone during the third week of pregnancy has been shown
to induce permanent overexpression of hepatic PEPCK in the F1 offspring, with no
significant effect on other gluconeogenic enzymes (Nyirenda et al 1998); PEPCK
expression is altered from day 5 of postnatal life, and remains elevated at 8 months
(Nyirenda et al 1998). PEPCK is the rate-limiting enzyme of gluconeogenesis (Pilkis
& Granner 1992), and transgenic mice with overexpression of hepatic PEPCK have
impaired glucose tolerance (Valera et al 1994). In addition, over-expression of
PEPCK in a rat hepatoma cell line impairs suppression of gluconeogenesis by insulin
(Rosella et al 1993). It has therefore been proposed that the increase in PEPCK in
programmed animals may increase hepatic gluconeogenesis, contributing to the
glucose intolerance reported in these animals (Nyirenda et al 1998). The mechanism
behind this programmed increase in PEPCK is unclear, but may be mediated by the
reported increase in hepatic glucocorticoid receptor number (Nyirenda et al 1998), in
association with normal or increased plasma glucocorticoid levels.
80
The postnatal growth trajectories of the F1 dex animals revealed a sexually
dimorphic pattern. The F1 dex males achieved catch-up growth by weaning, whereas
the F1 dex females remained smaller throughout the period of follow-up (1 year).
Previous reports have noted different growth patterns in rats exposed to
dexamethasone during the last week of gestation. Catch-up growth has been reported
to be complete (Nyirenda et al 1998, Welberg et al 2001) or incomplete (Cleasby et
al 2003a) in different groups of animals receiving the same antenatal treatments.
Postnatal growth has been proposed to be an important factor modifying the risk of
subsequent disease associated with low birth weight. In some human studies, slow
growth during the first year of life has been associated with an increased risk of
cardiovascular disease in later life (Eriksson et al 2001), although a recent study has
suggested that rapid growth during the first two weeks of life may also be associated
with an increased risk of cardiovascular disease (Singhal et al 2003). Increased
growth in the first two years of life is associated with an increased risk of obesity in
childhood, which may be a predisposing factor to obesity in adulthood (Ong et al
2000). Furthermore, accelerated growth during childhood, after the first year,
increases the risk of hypertension, type 2 diabetes and coronary heart disease
(Eriksson et al 1999, Eriksson et al 2000, Forsen et al 2000, Eriksson et al 2001,
Eriksson et al 2002, Law et al 2002, Eriksson et al 2003). Factors governing
postnatal catch-up growth and the mechanisms by which it modifies disease risk
remain unclear, although potential mechanisms include programming of appetite
and/or obesity (reviewed in Breier et al 2001), or modification of postnatal growth
and metabolism by genetic factors (reviewed in Ong & Dunger 2002).
The role of catch-up growth in modifying the phenotype of the glucocorticoid-
programmed rat is unclear. In addition to studies demonstrating the programming
effects of in utero glucocorticoid overexposure in the last week of gestation, rats
exposed to excess glucocorticoid throughout gestation, either by maternal
administration of dexamethasone or carbenoxolone (which inhibits placental lip-
HSD), demonstrate reduced birth weights (Benediktsson et al 1993, Lindsay et al
1996a, Lindsay et al 1996b, Nyirenda et al 1998, Welberg et al 2000, Welberg et al
2001) but different patterns of postnatal growth (Lindsay et al 1996b, Nyirenda et al
1998, Welberg et al 2000, Welberg et al 2001). Nevertheless, programmed effects on
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glucose tolerance and behaviour have been reported in groups of animals in the
different programming paradigms, with or without postnatal catch-up growth
(Lindsay et al 1996b, Nyirenda et al 1998, Welberg et al 2000, Welberg et al 2001,
Cleasby et al 2003a).
No differences were noted in glucose tolerance or basal corticosterone levels in F1
animals. Some, but not all, studies have noted an increase in basal corticosterone
level in dexamethasone-programmed animals (Levitt et al 1996, Nyirenda et al
1998). No difference was detectable in blood pressure in F1 males or females,
although technical difficulties meant that blood pressure was only measured in a
small number of F1 males. The lack of an effect on glucose homeostasis, and on
plasma corticosterone levels, may indicate that the programming effect in this F1
cohort was relatively mild. Additionally, experience in our laboratory over some
years suggests that external stressors, such as building work near to the animal unit,
or ultrasonic noise from lighting systems can result in cohort differences in values in
the placebo treated groups.
Birth weight was reduced in the F2 dex offspring and in addition, hepatic PEPCK
was significantly increased. This marked effect in the F2 generation appears to have
occurred despite amild programming phenotype in the F1 dex parents.
In contrast to the lack of any detectable effect on glucose homeostasis in the F1
generation, at four months of age the F2 dex males demonstrated higher glucose
levels at 30 minutes following a glucose load. Previous studies in F1 animals have
not been able to show evidence of glucose intolerance in animals exposed to
dexamethasone in utero until 6 months of age (Dr M Nyirenda, unpublished data).
By six months, the F2 dex males had elevated basal plasma insulin levels and an
elevated fasting insulimglucose ratio, indicating insulin resistance. In the females, the
effect was less clear, although there was a trend for an elevation in fasting
insulimglucose ratio at 6 months. The observed glucose intolerance in the F2 animals
may be explained in part by programmed hepatic PEPCK overexpression leading to
increased gluconeogenesis. A recent study, while demonstrating reduced glycogen
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storage in the muscle of F1 dex animals, did not find evidence of reduced peripheral
glucose uptake and found no difference in protein levels of the glucose transporter
GLUT-4 in the muscle of programmed animals (Cleasby et al 2003a). Glucose
uptake into adipose tissue was similarly unchanged (Cleasby et al 2003a). These
results suggest that enhanced hepatic glucose output may be the main factor in
determining the programmed hyperglycaemia observed in the programmed animals.
Consistent with this observation, the F2 dex animals in this study showed evidence
of glucose intolerance in addition to a marked elevation in PEPCK activity, in
contrast to the F1 dex animals, which showed normal glucose tolerance (at least in a
glucose tolerance test) and a trend for elevated PEPCK activity.
There were no detectable programming effects in the third generation, in which there
were no differences in birth weight and subsequent growth patterns, hepatic PEPCK
activity or glucose tolerance between F3 dex and F3 veh animals.
There are a number of possible explanations for this intergenerational phenomenon,
as discussed in chapter one, including programmed effects in the mother, resulting in
the exposure of the fetus to an adverse environment in utero, and thus perpetuating
the programming effects in subsequent generations. Maternal size has been shown to
be an important determinant of fetal size in early studies using shire horses and
Shetland ponies (Walton & Hammond 1938), and in human studies (Cawley et al
1954). Additionally, it has been suggested that poor maternal intrauterine growth is
associated with reduced weight gain during pregnancy (Hackman et al 1983), and
that girls born small for gestational age who remain small have reduced uterine and
ovarian size (Ibanez et al 2000). Indeed, in this study maternal size was reduced in
the F1 dex mothers at the time of conception.
It has also been proposed that maternal blood pressure might influence fetal growth,
indeed in human studies, lower maternal birth weight is associated with an increased
risk of hypertension during pregnancy (Klebanoff et al 1999) and higher maternal
blood pressure during pregnancy is associated with lower offspring birth weight
(Churchill et al 1997, Ferrer et al 2000, Brown et al 2001, Buchbinder et al 2002).
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Maternal birth weight is related to offspring blood pressure (Barker et al 2000) and
higher maternal blood pressure later in life is also associated with higher offspring
blood pressure (Walker et al 1998), suggesting that a programmed increase in blood
pressure might have intergenerational effects on fetal growth and subsequent disease.
In a recent animal study, blood pressure was higher in the female offspring of rabbits
with surgically induced hypertension (Denton et al 2003), suggesting a specific
intergenerational effect of higher maternal blood pressure on offspring blood
pressure. However, in the study described in this chapter, no differences were found
in maternal blood pressure in F1 or F2 female offspring; programmed effects on
blood pressure were only seen in males in the F2 generation. Although this suggests
that programmed changes in blood pressure are unlikely to play an important role in
intergenerational effects in the F2 generation in this model, specific effects acting
during pregnancy cannot be excluded.
In view of the known effect of fetal overexposure to glucocorticoids to programme
offspring hypercorticosteronaemia (Nyirenda et al 1998), elevated maternal
glucocorticoid levels might play a role in the transgenerational programming of birth
weight, PEPCK, glucose intolerance and blood pressure. Indeed, non-genetic
intergenerational transmission of behavioural and HPA responses to stress,
hypothalamic CRH and hippocampal GR expression has been reported in rats
(Francis et al 1999). However, in our study, there was no evidence of
hypercorticosteronaemia in the F1 dex females, although again this does not rule out
a specific effect during pregnancy or the possibility that average levels across a full
diurnal rhythm, or peak levels could be increased.
In animal models of diabetes and in models of programming by nutrition,
intergenerational effects have been noted on glucose tolerance and the development
of the endocrine pancreas (Hoet & Hanson 1999, Martin et al 2000, Fowden & Hill
2001, Van Assche et al 2001). In utero exposure to a low protein diet or maternal
food restriction results in impaired pancreatic P-cell development in the offspring
(Snoeck et al 1990, Dahri et al 1991, Garofano et al 1997, Garofano et al 1998), with
impaired glucose tolerance in adulthood (Dahri et al 1991, Garofano et al 1999) and
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an inability to increase insulin production during pregnancy (Dahri et al 1995,
Blondeau et al 1999). F2 offspring of protein-restricted animals also have abnormal
pancreatic development (Hoet & Hanson 1999, Reusens & Remacle 2001). Thus,
these studies demonstrate that exposure to an unfavourable uterine environment may
affect pancreatic development in a second generation.
Furthermore, second generation effects on glucose tolerance and body weight have
been demonstrated in the offspring of females rendered hyperinsulinaemic and obese
as a result of rearing on a high carbohydrate milk formula during their suckling
period (Laychock et al 1995, Srinivasan et al 2003). These studies suggest that
exposure to a hyperinsulinaemic environment in utero is sufficient to programme
hyperinsulinaemia and obesity in the offspring.
In humans, maternal glucose metabolism can have a profound effect on offspring
birth weight, and on later diabetes risk. Maternal blood glucose levels are directly
related to fetal weight, including glucose values within the normal range (Farmer et
al 1988, Breschi et al 1993) and maternal diabetes is generally associated with fetal
overgrowth or 'macrosomia', although the presence of severe complications of the
disease can result in intrauterine growth retardation (reviewed in Van Assche et al
2001). Thus, insulin resistance associated with glucose intolerance tends to increase
birth weight in the offspring. However, hyperinsulinaemia without glucose
intolerance might be a cause of fetal undernutrition (Breschi et al 1993). Indeed,
some studies in humans have found that higher maternal fasting insulin is associated
with lower offspring birth weight (Breschi et al 1993, Baur et al 1999). In the study
described in this chapter, no differences were seen in glucose and insulin levels in the
F1 females, arguing against a role for hyperinsulinaemia in the intergenerational
effects described.
There were a number of gender differences in this model of programming. F1 dex
females did not demonstrate full catch-up growth, unlike the F1 dex males. There
were also gender differences in the F2 generation; males appeared to be more
susceptible to intergenerational effects than females. F2 dex males had higher blood
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pressure and more striking glucose intolerance than the F2 dex females. A number of
sex-specific effects have been described in animal models of fetal programming
(Hales et al 1996, Dean & Matthews 1999, Kind et al 1999, Lingas et al 1999, Smith
& Waddell 2000, Dean et al 2001, Lingas & Matthews 2001, Liu et al 2001, Owen &
Matthews 2003). In some paradigms, females have been more sensitive to
programming effects; exposure to excess glucocorticoid in utero delays puberty in
female (but not male) rats (Smith & Waddell 2000) and female offspring of
hypertensive female rabbits have elevated blood pressure, whereas males are
normotensive (Denton et al 2003). Human studies have revealed some sex
differences in the long-term disease risk associated with low birth weight (Forsen et
al 2000, Walker et al 2002), or exposure to famine prenatally (Ravelli et al 1999).
Such sex-specific effects may represent the differential sensitivity of males and
females to programming phenomenon and indeed, stronger programming in females
may further amplify a matrilineal pattern of intergenerational inheritance.
In conclusion, this study has demonstrated an intergenerational effect of
glucocorticoid programming on birth weight, hepatic PEPCK, glucose tolerance and
blood pressure in the second generation in rats. The programming effects appear to
be stronger in the F2 generation than in F1 animals, and in male offspring, and are no
longer evident in a third generation. However, this experiment has not explored in
any detail the potential for parent-specific effects on subsequent generations.
Although programmed alterations in maternal physiology might impact upon a
developing fetus, leading to intergenerational programmed effects, we have not
excluded a paternal effect on offspring phenotype. Although the mother may
influence offspring development by genetic or environmental mechanisms, clearly
the major paternal influence in this experiment is through genomic mechanisms. The
paternal role in intergenerational effects will be addressed in chapter four.
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Chapter Four - The influence of paternal phenotype on
intergenerational programming effects.
4.1 Introduction
Although there is evidence for a greater maternal influence on offspring
characteristics, there is clearly also an influence of the father on offspring birth
weight and the later development of cardiovascular disease (Emanuel et al 1992,
Davey Smith et al 1997, Klebanoff et al 1998, Magnus et al 2001, Kinra et al 2003,
Lawlor et al 2003b) and on type 2 diabetes risk (Mitchell et al 1995, McCarthy et al
1996, Viswanathan et al 1996, Meigs et al 2000, Yajnik et al 2001, Hypponen et al
2003). Indeed, as discussed in chapter one, in the Pima Indian Community, low birth
weight is associated with the subsequent development of type 2 diabetes, but only if
paternal diabetes is also present.
In chapter three we demonstrated the intergenerational programming effects of in
utero overexposure to glucocorticoids on birth weight, PEPCK and glucose
tolerance. We have used the same model to investigate whether these
transgenerational effects are mediated exclusively via programmed changes in
maternal physiology, which would therefore be inherited through the maternal line,




To investigate the effect of paternal phenotype on the offspring in more detail, a new
F1 cohort was generated using the methods described in chapter three. For the F1
breeding, F1 females weighing around 230-250g were timed-mated with F1 males as
follows: 8 F1 dex females were timed-mated with F1 dex males (dex/dex crosses)
and 8 F1 veh females with F1 veh males (veh/veh crosses), giving 8 litters per group.
A further group of 5 F1 dex females were timed-mated with F1 veh males (dex/veh
crosses), and 6 F1 veh females with F1 dex males (veh/dex crosses). Females were
caged separately during pregnancy and not manipulated in any way; all produced
litters. Pups were weighed and culled to eight at birth and weaned at 3 weeks. All
offspring were weighed at weaning and monthly thereafter.
At five weeks (Fl) or three weeks (F2) of age, male animals from each group (n=8-
10) were selected randomly from as many litters as possible. They were culled by
cervical dislocation and tissues dissected and snap-frozen on dry ice. Portions of liver
were collected into Eppendorfs and placed on wet ice for PEPCK analysis.
Data are expressed as mean ± SEM unless otherwise stated. Data were analysed
using unpaired t tests, 2-way or repeated measures ANOVA (glucose tolerance tests,




4.3.1 Birth weights and postnatal growth
Birth weights were significantly reduced in F1 dex offspring in this cohort (Table
4.1). Females receiving dexamethasone gained less weight during the last week of
gestation, but there was no change in gestation length, litter number or the proportion
ofmale and female pups (Table 4.1).
F1 dex males achieved full catch-up growth by 2 months of age and, in contrast to
the experiment described in chapter three, F1 females also achieved full catch-up
growth by 4 months of age (Figure 4.1).
4.3.2 F1 PEPCK
There were no differences in hepatic PEPCK activity between male F1 dex and F1
veh animals (Table 4.1).
Dex Veh P value
F1 Birth weight (g) 5.34 ± 0.04 6.01 ± 0.07 <0.001
F1 Gestation length
(days) 20.6 ±0.2 21.1 ±0.2 0.062
F1 Litter number 14.7 ±0.7 14.8 ±1.2 0.96
Maternal weight gain (g) 61.8 ±3.8 88.2 ± 8.4 0.018
PEPCK activity 10.8 ±0.5 9.9 ±1.0 0.44
(nmol/min/mg protein)
Table 4.1 Data for F1 cohort.
Data are for 10 F1 dex and 9 F1 veh litters. Birth weights for 147 F1 dex and 133 F1
veh pups. PEPCK activity was measured on fresh liver homogenates at 5 weeks on
male animals (n=8 F1 dex and 7 F1 veh). Data were analysed by Student's t test.
89
Figure 4.1 Postnatal growth in F1 cohort.
Growth in F1 males (panel A, n= 50 per group at 1 month, 8 per
group thereafter) and females (panel B, n=22-25 per group at 1
months, 14-20 at 2-3 months, 6 per group thereafter).
Data were analysed by ANOVA. Post hoc analysis revealed persistent
differences in weight between dex and veh males only at weaning,





4.3.3 Birth weight and postnatal growth in F2 animals
In contrast to the experiment described in chapter three, in which F1 dex females had
been significantly lighter at the time ofmating, there were no differences in maternal
body weights between the F1 dex and F1 veh females at gestation day EO in this
experiment (Table 4.2). There were no differences in maternal weight gain, gestation
length or litter number in any of the breeding groups (Table 4.2).
As in the previous F2 cohort, birth weights were lower in the F2 offspring of dex/dex
crosses (F2 dex/dex) when compared with F2 offspring of veh/veh crosses (F2
veh/veh), although the effect was not as marked as before (Table 4.2).
More striking differences were noted in the offspring of crosses between F1 dex and
F1 veh males and females. Litter size was more variable than with dex/dex or
veh/veh crosses (Table 4.2). Birth weights of the offspring of F1 dex mothers crossed
with F1 veh fathers (F2 dex/veh) were not different from those of dex/dex crosses;
however birth weights of the offspring of F1 veh mothers crossed with F1 dex fathers
(F2 veh/dex) were lower than those in all other groups (Table 4.2).
There were no differences between body weights in any of the groups at weaning, i.e.
males and females in all groups had achieved catch-up growth.
4.3.4 PEPCK
As in the previous F2 cohort, hepatic PEPCK activity was elevated in male offspring
of dex/dex crosses (F2 dex/dex) when compared with the offspring of veh/veh
crosses (Figure 4.2)
PEPCK activity in the F2 offspring of veh mothers and dex fathers (F2 veh/dex) was
elevated when compared to the offspring of veh/veh crosses, reaching the same value
as that of the dex/dex crosses. PEPCK activity in the offspring of dex mothers and
veh fathers (F2 dex/veh) was almost 3 fold higher than that in the offspring of
veh/veh crosses (Figure 4.2).
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Litter F2 veh/veh F2 dex/dex F2 veh/dex F2 dex/veh
Mother veh dex veh dex
Father veh dex dex veh
Gestation 22.3 ±2 22 ±0 21.5 ±0.7 22.4 ±0.2
(days)
Litter no. 15.8 ±0.4 14.8 ±0.8 13.2 ±2.2 13.6 ±2.2
Maternal 286 ±7 265 ± 13 282 ±8 279 ± 10
wt EO
Maternal 150 ±7 146 ± 6 154 ± 13 137 ± 11
wt gain (g)
Birth wt (g) 6.15 ±0.05 5.92 ±0.05 5.71 ±0.09 5.96 ±0.08
Table 4.2 F2 data
Data are mean ± SEM. Analysis by ANOVA revealed no differences between the
groups for gestation length, litter number, maternal weight at EO or maternal weight
gain. Litters were obtained for 8 veh/veh, 8 dex/dex, 5 dex/veh and 6 veh/dex
crosses.
Analysis by ANOVA of birth weights in offspring of veh/veh (n=126), dex/dex
(n=l 16), veh/dex (n=71) and dex/veh (n=62) crosses revealed that birth weights were
lower in the offspring of dex/dex crosses (F2 dex/dex) when compared with F2
offspring of veh/veh crosses (F2 veh/veh) (p<0.05). Birth weights of the offspring of
F1 dex mothers crossed with F1 veh fathers (F2 dex/veh) were also lower than F2
veh/veh (p<0.05), but were not different from those of dex/dex crosses. Birth weights
of the offspring of F1 veh mothers crossed with F1 dex fathers (F2 veh/dex) were
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Figure 4.2 Hepatic PEPCK activity in F2 males.
PEPCK activity was measured in fresh liver homogenates at 3 weeks of
age. N = 8 per group for F2 dex/dex and F2 veh/veh, 7 per group for F2
veh/dex (veh mother x dex father) and dex/veh (dex mother x veh father).
Data were analysed by ANOVA; * p<0.05.
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4.4 Discussion
The data presented in this chapter confirm an intergenerational effect on birth weight
and hepatic PEPCK activity in the dexamethasone programmed rat and additionally,
reveal an intriguing paternal effect on birth weight and PEPCK activity in the F2
generation.
Consistent with the findings described in chapter three, birth weight was reduced and
hepatic PEPCK activity elevated in F2 dex offspring, compared to F2 veh offspring.
F1 and F2 offspring birth weights in this experiment tended to be higher than those in
the original, which may reflect the variability of birth weight in the relatively outbred
strain of animals used. Indeed, other reports using the same model have reported
different birth weights in the F1 offspring (Nyirenda et al 1998, Welberg et al 2001,
Cleasby et al 2003a). In addition, F1 females in this cohort achieved full catch-up
growth by four months of age, and there were no differences between groups in
maternal weight at gestational day E0, excluding a major effect of maternal size in
intergenerational programming effects in this model.
In addition to confirming an intergenerational effect of dexamethasone
programming, this experiment has demonstrated a significant influence of paternal
phenotype on birth weight and PEPCK activity. In the F2 offspring of F1 dex
females, there was no additional effect of paternal phenotype on birth weight; birth
weights of the offspring of F1 dex females were no different between the groups
fathered by F1 dex and F1 veh males. However, in the offspring of dex females,
there was a marked effect of paternal phenotype on offspring PEPCK activity, such
that the paternal dex phenotype attenuated the increase in hepatic PEPCK activity
seen in the offspring of dex mothers and veh fathers. In contrast, in the F2 offspring
of F1 veh females, paternal dex significantly reduced birth weight and increased
PEPCK.
Most studies of intergenerational effects in animal models of programming have
concentrated on the consequences of interventions in the mother (Pinto & Shetty
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1995, Francis et al 1999, Martin et al 2000, Patel et al 2001, Denton et al 2003,
Srinivasan et al 2003) and second generation effects on glucose tolerance and blood
pressure have been demonstrated in the offspring of females crossed with males in
the same treatment group (Laychock et al 1995), or untreated males (Denton et al
2003, Srinivasan et al 2003). The authors of these studies have suggested that in
utero exposure to an adverse maternal environment resulted in programmed
alterations in the development of the endocrine pancreas (Laychock et al 1995,
Srinivasan et al 2003) and in the renin-angiotensin system (Denton et al 2003).
These effects observed here on birth weight and PEPCK activity in the F2 offspring
demonstrate that the father also has an effect on the intergenerational transfer of
disease risk in this model. Thus, it would appear that the intergenerational effects
described in this study might not be explained entirely by the exposure of the fetus to
a programmed adverse maternal environment. Alterations in the DNA sequence are
unlikely to occur rapidly enough to explain intergenerational effects that are
transmissible from both parents and additionally, the phenotype is attenuated in the
third generation. One potential mechanism is 'epigenetic' modification, which may
affect the phenotype without changing the DNA sequence, mediated by alterations in
DNA methylation and histone modification, which influence transcriptional activity
and gene expression (Rakyan et al 2001, Li 2002). In humans, alterations in the
expression of imprinted genes can lead to a number of recognised syndromes,
including some associated with altered patterns of growth, for example Beckwith-
Wiedemann, Prader-Willi and Silver-Russell syndromes (for review see Preece &
Moore 2000). Indeed, imprinting of genes has been proposed as the mechanism
behind the association of lower offspring birth weight with paternal diabetes in the
Pima Indian population (Lindsay et al 2000, Lindsay et al 2002a), and in the parental
differences seen in the transmission of class III alleles of the INS-VNTR, which has
been associated with type 2 diabetes (Huxtable et al 2000). However, epigenetic
modification is not restricted to parentally imprinted genes and recent evidence
suggests that epigenetic modifications at some other alleles may not be completely
erased during gametogenesis and embryogenesis, potentially resulting in the
intergenerational inheritance of the epigenetic state (Roemer et al 1997, Morgan et al
95
1999). Indeed, one study has demonstrated phenotypic alterations in mice
corresponding with differential methylation, which shows transgenerational
epigenetic inheritance after both paternal and maternal transmission of the relevant
allele, displays parent of origin effects and is influenced by the strain background
(Rakyan et al 2003).
How might these epigenetic changes arise? Environmental influences may affect
gene expression and have effects on growth (Reik et al 1993, Dean et al 1998,
Khosla et al 2001, Young et al 2001, Reik et al 2003). Indeed, maintaining pregnant
mice on a diet rich in methyl donors profoundly affects the phenotype in Agouti
Yellow mouse pups by increasing methylation of the agouti gene (Waterland & Jirtle
2003). Recent evidence suggests that glucocorticoids may influence gene expression;
glucocorticoids regulate DNA demethylation within an enhancer of the rat liver-
specific tyrosine aminotransferase (TAT) gene in cell culture, the gene remains
demethylated following hormone withdrawal and a stronger response to subsequent
glucocorticoid exposure indicates that this demethylation may provide some
'memory' of a regulatory event during development (Thomassin et al 2001).
Furthermore, there is some evidence for differential methylation of the GR gene in
association with different patterns of maternal behaviour in the rat which have
intergenerational consequences (Weaver et al 2002). Thus, glucocorticoids may
induce epigenetic modifications, potentially leading to intergenerational effects on
fetal growth and later disease risk.
The data also indicate that there is not a straightforward association between birth
weight and PEPCK, although offspring with a reduced birth weight have higher
PEPCK activity, offspring with the lowest birth weight (F2 veh/dex) were not those
with the highest PEPCK activity. Thus, the results suggest that different mechanisms
may be operating to reduce fetal size and influence subsequent PEPCK activity. In
addition, it is possible that the marked paternal effect on offspring phenotype may be
by a different, additional pathway to maternal effects; the maternal influence on
offspring may be due to effects on the fetal environment and/ or act via genomic
mechanisms.
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In conclusion, we have shown an effect of paternal early life experience on offspring
characteristics in this animal model of programming. The mechanisms underlying
this effect are unclear, but could include inherited epigenetic effects. In support of
this hypothesis, there is recent evidence that epigenetic modifications of the genome
can be transmitted from both parents, with some studies demonstrating parent of
origin effects. Environmental factors, including glucocorticoids, could change the
pattern of DNA methylation and chromatin remodelling, perhaps altering the
expression of imprinted genes in the placenta, the fetus, or both, affecting fetal
growth and later disease risk. Furthermore, these effects could be amplified by the
subsequent in utero or postnatal environment.
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Chapter Five - Diet-induced obesity in the Wistar rat
5.1 Introduction
In animal models and in human studies, obesity appears to be an important amplifier
of the programming effect (Phillips et al 1994, Lithell et al 1996, Leon et al 1998,
Vickers et al 2000, Vickers et al 2001b, Eriksson et al 2002, Eriksson et al 2003). In
human studies and in some animal models, obesity is associated with alterations in
glucocorticoid metabolism (Livingstone et al 2000a, Rask et al 2001, Rask et al
2002, Wake et al 2003). Thus, the dexamethasone-programmed rat, in which the
programming effect is associated with, and may be dependent on, altered
glucocorticoid signalling (Nyirenda et al 1998), may be more susceptible to the
development of obesity and its complications. In this chapter we describe the
development of a model of diet-induced obesity in Wistar rats, which we have
subsequently used to explore the effects of obesity on the dexamethasone-
programmed rat (described in chapter six). While developing this model we sought to
explore whether dietary-induced obesity induces the same changes in glucocorticoid
signalling as those seen in genetic obesity and whether the time course of changes in
dietary obesity might provide any insight into the underlying mechanisms.
A number of studies in animal models have sought to determine whether
abnormalities in glucocorticoid secretion, action or metabolism may underlie the
development of visceral adiposity and the metabolic syndrome. The importance of
glucocorticoids in the pathogenesis of obesity is underlined by the observations that
the obese phenotype is ameliorated by adrenalectomy or treatment with
glucocorticoid receptor antagonists in several animal models (Yukimura et al 1978,
Freedman et al 1986, Langley & York 1990, Makimura et al 2000). Extensive studies
in the obese Zucker rat have demonstrated increased activity of the HPA axis (White
et al 1989, Guillaume-Gentil et al 1990, Havel et al 1996, Timofeeva et al 1999,
Livingstone et al 2000a, Livingstone et al 2000b, Mattsson et al 2003), increased
reactivation of glucocorticoids by lip-HSD 1 in adipose tissue, but impaired
reactivation in the liver (Livingstone et al 2000a) and increased glucocorticoid
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inactivation by hepatic A-ring reductases (Livingstone et al 2000a). Very recently,
downregulation of 11 (3-HSD 1 has been demonstrated in the hippocampus of obese
Zucker rats, suggesting a role for alterations in this enzyme in impaired negative
feedback on the HPA axis (Mattsson et al 2003). Obesity in leptin deficient ob/ob
mice is also associated with hypercorticosteronaemia, insulin resistance and
decreased hepatic 1 ip-HSD 1 (Liu et al 2003).
Glucocorticoid action is mediated by low-affinity GR and high-affinity MR;
alterations in receptor numbers or binding may affect both peripheral glucocorticoid
action and central glucocorticoid feedback. Previous studies of glucocorticoid
receptor characteristics in the obese Zucker rat have reported normal or reduced
hepatic GR number and affinity (Shargill et al 1987, White & Martin 1990, Langley
& York 1992) and reduced MR but normal GR in the hippocampus, which may
contribute to the increased HPA activity and appears to be important under
conditions of stress (Mattsson et al 2003).
5.2 Methods
Eight female Wistar rats weighing around 250g were timed-mated with Wistar males
and caged separately throughout gestation. No manipulations were performed during
pregnancy.
At weaning (3 weeks), male offspring were weighed, and four males randomly
selected from each litter. Two males from each litter were weaned on to a high fat
diet (HF) (Diet D12451, Research Diets, New Brunswick, New Jersey), and two onto
a control diet (C) (Diet D01072401, Research Diets) (Section 2.20). Animals were
weighed weekly and handled daily for 2 weeks prior to investigation. Eight rats on
each diet were investigated after 3 weeks on the diet (Acute) and the remainder after
20 weeks on the diets (Chronic). After investigation at each time point, the animals
were culled by decapitation between 0900 h and 1100 h following an overnight fast,
and trunk blood was collected. Tissues were dissected immediately, weighed and
snap-frozen on dry ice.
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In a separate experiment, 12 male Wistar rats were commenced on the high fat and
12 on the control diet at 6 weeks of age. After 24 hours on the diets, 6 control and 6
high fat fed animals were weighed, sacrificed and tissues dissected as before; the
remaining 6 animals in each group were investigated after 72 hours on the diets.
Rats in the acute group underwent glucose tolerance testing at 3 weeks and those in
the chronic group at 20 weeks. Glucose was determined by the enzymatic
(hexokinase) method. Plasma insulin and leptin concentrations were determined by
ELISA. Triglycerides and non-esterified fatty acids were determined on plasma from
trunk blood samples using kits by Dr Philip Wenham, Department of Biochemistry,
Western General Hospital. Plasma corticosterone was measured by RIA on tail nick
blood samples taken at 0800 h and 1900 h.
3 3
lip-HSD 1 activity was estimated by conversion of [ H]-corticosterone to [ H]-ll-
dehydrocorticosterone and analysed by TLC (liver, omental and subcutaneous fat
from acute and chronic experiments) or HPLC (liver and fat depots from 24/72 hour
experiments). 5p-reductase was measured by conversion of [3H]-corticosterone to
[3H]-5p-tetrahydrocorticosterone and analysed by HPLC.
nrRNA was quantified by Northern blot (hepatic 5a- and 5p-reductase) or real-time
PCR (1 lp-HSD 1 and GR in all depots; 5a-reductase in omental fat).
Data are expressed as mean ± SEM unless otherwise stated. Data were analysed
using unpaired t tests, 2-way or repeated measures ANOVA (glucose tolerance tests,
longitudinal body weight) where appropriate. Significance was set at P of 0.05 or
less. N=8 for control and high fat at 3 weeks, 7 control and 8 high fat at 20 weeks,




After 24 hours, 72 hours and 3 weeks, HF rats showed no differences in body weight
or in organ weight (Table 5.1), however from 60 days HF rats had higher body
weights (Figure 5.1). At culling, HF rats had increased retroperitoneal fat weight
(Table 5.1), but no differences in the weight of other organs measured.
5.3.2 Glucose tolerance and lipids
After 3 weeks, HF rats were glucose intolerant, but had no difference in plasma
insulin levels (Figure 5.2). After 20 weeks, HF rats remained hyperglycaemic and in
addition, were markedly hyperinsulinaemic (Figure 5.2).
HF rats showed a trend towards lower plasma triglycerides (TG) after 3 weeks and a
significant decrease after 20 weeks. There were no differences in non-esterified fatty
acids (FFA) at either time point (Table 5.1).
There were no significant differences in plasma leptin at 3 or 20 weeks, although
there was a trend towards an increase in HF animals by 20 weeks (Table 5.1).
5.3.3 HPA axis
There were no differences in basal or peak plasma corticosterone levels after 3 weeks
(Figure 5.3). At 20 weeks, there were no differences in basal corticosterone levels,
but HF rats had lower peak plasma corticosterone (Figure 5.3).
There were no differences in mRNA for hepatic or omental fat GR at 3 or 20 weeks
(Table 5.2).
101
21 35 49 63 77 93 107 121 135
Age (days)
Figure 5.1 Body weights of rats on high fat (HF) and control (C) diets.
Data were analysed by repeated measures ANOVA. Rats on HF diet were
significantly heavier from 60 days (p = 0.03). N=7 control and 8 high fat.
□ Control diet
■ High Fat diet
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3 weeks 20 weeks
Control High fat Control High fat
BW (g) 188 ±10 194 ±9 541 ±20 618 ± 17 f
RP fat wt (g) 1.1 ±0.2 1.5 ±0.4 12.9 ±0.9 21.7 ± 1.9fff
Leptin ng/ml 0.7 ±0.1 0.8 ±0.1 2.4 ±0.4 3.2 ± 0.2
Serum (mM)
Fatty acids 0.49 ± 0.06 0.43 ± 0.02 0.50 ± 0.03 0.49 ± 0.04
Triglycerides 1.3 ±0.2 0.9 ±0.1 2.0 ±0.4 1.3 ± 0.1 |
Table 5.1 Weight and plasma parameters for animals on HF and C diets.
Body weight (BW), retroperitoneal fat weight (RP) and plasma parameters from
animals at 3 weeks (n= 8 C and 8 HF) and 20 weeks (n= 7 C and 8 HF).
Data are the mean ± SEM. f indicates a significant difference between high fat and
control groups at 20 weeks (f, P<0.05; ff f, P<0.005).
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Figure 5.2 Glucose tolerance test after 3 and 20 weeks on HF and C diet.
Plasma glucose (panel A) and insulin (panel B) after 3 weeks (n=8 per
group), plasma glucose (panel C) and insulin (panel D) after 20 weeks (n=
7 C and 8 HF).
Data were analysed by ANOVA * denotes p<0.05 comparing HF and C.
□ Control diet










0800 h 1900 h
Time
□ Control diet
■ High Fat diet
Figure 5.3 Plasma corticosterone levels.
Plasma levels at 0800 h (basal) and 1900 h (peak) after 3 weeks (n=
8 per group) (panel A) and 20 weeks (n= 7C and 8 HF) (panel B).
Analysis by ANOVA showed no effect of diet or time on basal
corticosterone levels, but an effect of HF to decrease peak levels by
20 weeks (p<0.05). Peak corticosterone levels at 20 weeks were
higher than at 3 weeks in both HF and C (p<0.05) (*denotes p<0.05
comparing HF and C).
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5.3.4 11/3-HSD 1
At 24 and 72 hours there were no differences in hepatic or omental fat 1 ip-HSD 1
activity between HF and C animals, although after 72 hours there was a trend
towards a decrease in activity in subcutaneous fat from HF rats (Figure 5.4).
By 3 weeks, HF rats had lower lip-HSD 1 activity in liver, subcutaneous and
omental fat (Figure 5.5). After 20 weeks, differences in lip-HSD 1 activities were
no longer apparent (Figure 5.5).
There were no differences at 3 or 20 weeks in mRNA levels for hepatic and omental
fat lip-HSD 1 (Table 5.2)
5.3.5 A-ring reductases1
HF rats had higher hepatic 5p-reductase activity after 24 hours on the diet, and a
trend towards a decrease at 72 hours which did not reach significance. The increase
in activity noted at 24 hours was maintained at 3 weeks (Figure 5.6).
After 20 weeks, there was no difference in hepatic 5p-reductase activity (Figure 5.6).
There were no differences at 3 or 20 weeks in mRNA levels for hepatic and omental
fat 5a-reductase or hepatic 5P-reductase (Table 5.2).
1 Measurement of 5a-reductase mRNA in omental fat by real time PCR was carried out by Caroline
Elferink, and measurement of hepatic 5P-reductase activity in tissues from 3 and 20 weeks was
performed by Lisa Reidy, both visiting undergraduates in the Endocrine Unit.
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3 weeks 20 weeks



































Liver 1.69 ±0.09 1.76 ±0.08 2.62 ±0.12 2.24 ±0.17
Table 5.2 11 (3-HSD 1, GR and A-ring reductase mRNA data.
GR and lip-HSD 1 mRNAs were quantified by real time PCR and are expressed
normalised to cyclophilin.
5a-reductase and 5P-reductase mRNAs were quantified by Northern Blot in liver
and are expressed normalised to Ul. 5a-reductase mRNA was quantified by real
time PCR in omental fat, and is expressed normalised to cyclophilin.
N= 8 per group at 3 weeks and 7 C and 8 HF at 20 weeks. Data are mean ± SEM and
were analysed by Student's t test.
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liver SC fat Om fat
(B)
liver SC fat Om fat
Figure 5.4 Tissue 11P-HSD 1 activity after 24 and 72 hours on HF and C diets.
lip-HSD 1 activity was measured in tissue homogenates, expressed as percent
conversion of corticosterone to 11 -dehydrocorticosterone after 24 hours (panel
A) and 72 hours (panel B). N= 6 per group.
SC = subcutaneous fat; Om = omental fat
Analysis by ANOVA revealed a trend towards a decrease in 11 p-HSD 1 activity
in subcutaneous fat after 72 hours (p=0.058).
□ Control diet
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3 weeks 20 weeks
Figure 5.5 Tissue 11 (3-HSD 1 activity after 3 and 20 weeks on HF and C diets.
11 (3-HSD 1 activity was measured in tissue homogenates, expressed as percent
conversion of corticosterone to 11-dehydrocorticosterone. N= 8 per group at 3
weeks and 7 C and 8 HF at 20 weeks.
SC = subcutaneous fat; Om = omental fat.
Data were analysed by Student's t test *denotes p<0.05 comparing HF and C.
□ Control diet



























3 weeks 20 weeks
□ Control diet
■ High Fat diet
Figure 5.6 Hepatic 5p-reductase activity.
5p-reductase activity after 24 and 72 hours (panel A) and after 3 and 20 weeks
(panel B). 5p-reductase was measured in tissue homogenates, expressed as
percent conversion of corticosterone to 5p-tetrahydrocorticosterone.
Analysis by ANOVA showed an effect of HF diet to increase 5p-reductase
activity at 24 hours (n=6 per group) and 3 weeks (n=8 per group), (* denotes
p<0.05 comparing HF and C), and a trend to increase activity at 72 hours
(p=0.09, n=7 C and 8 HF).
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5.4 Discussion
These results demonstrate that short-term high fat feeding in rodents is associated
with the development of insulin resistance and acute changes in glucocorticoid
metabolising enzymes, in the absence of obesity. In contrast, rodents maintained on a
long-term high fat diet are obese and insulin resistant, with altered activity of the
HPA axis, but no longer exhibit such striking changes in glucocorticoid metabolising
enzymes. Thus, the model does not show the same alterations in glucocorticoid
metabolism that are observed in genetic models of obesity such as the obese Zucker
rat (Livingstone et al 2000a), but does provide some insights into the regulation of
these enzymes. In addition, there were no changes in GR mRNA in liver or omental
fat at either time point, in contrast to the alterations in hepatic GR reported in the
insulin resistant dexamethasone-programmed rat (Nyirenda et al 1998) and in the
obese Zucker rat (White & Martin 1990).
In this study, long-term high fat feeding was associated with the development of
obesity and profound insulin resistance without basal hyperglycaemia, in agreement
with results from some (Tannenbaum et al 1997, Chalkley et al 2002, Commerford et
al 2002), but not all (Wang et al 1998), previous studies. The mechanisms by which
chronic high fat feeding induces insulin resistance remain unclear, but may include
the failure of insulin to suppress elevated muscle and liver lipid availability, with a
consequent reduction in insulin mediated glucose disposal in muscle and reduced
suppression of hepatic gluconeogenesis (Oakes et al 1997). Additionally, studies
have shown that high fat feeding is associated with reduced insulin-mediated
suppression of glucose-6-phosphatase and a chronic reduction in hepatic glucokinase
(Oakes et al 1997).
HF rats had a marked increase in the amount of retroperitoneal fat after 20 weeks.
Human studies have demonstrated that the preferential accumulation of visceral fat is
a more important predictor of increased morbidity and mortality than body mass
index or total body adipose mass (Montague & O'Rahilly 2000). Indeed, selective
reduction in visceral adiposity in humans by diet and exercise is associated with an
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improved cardiovascular risk profile (Riches et al 1999) and in animal models,
surgical removal of visceral fat (epididymal and perinephric fat pads) reverses
hepatic insulin resistance and hepatic glucose output (Barzilai et al 1999).
The metabolic syndrome in humans is associated with hypertriglyceridaemia,
however in this model, HF rats showed a reduction in plasma TG levels after 20
weeks, and no change in plasma FFAs. Although some studies have shown increased
serum FFA in rats on a high fat diet (Tannenbaum et al 1997), others have shown
decreased FFA and TG on high fat feeding (Kraegen et al 1991, Morin et al 1997,
Vickers et al 2001a, Chalkley et al 2002, Hegarty et al 2002, Picard et al 2002, Chen
& Nyomba 2003); this has been attributed to enhanced clearance of fatty acids into
muscle (Hegarty et al 2002). In addition, it has been suggested that fasting FFA
levels are extremely variable and appear to correlate poorly with measures of insulin
resistance (Steinberg et al 1997).
There were no differences in basal plasma corticosterone levels at 3 or 20 weeks. In
rodents, maintenance on a high fat diet led to increased basal plasma corticosterone
levels at 7 days in one study (Tannenbaum et al 1997), although another study did
not find this (Kamara et al 1998). Both studies failed to show any difference in basal
corticosterone levels after 21 days (Tannenbaum et al 1997, Kamara et al 1998). In
our study, peak plasma corticosterone levels were significantly reduced after 20
weeks on the high fat diet. Although short exposure (3 days) to a high fat diet does
not alter peak corticosterone levels (Kamara et al 1998), peak levels have been
shown to decline after 5 weeks in rats maintained on a diet containing more than
30% fat (Wang et al 1998). Additionally, in rats, stress induced HPA axis activity is
altered by short- and long-term exposure to a high fat diet (Tannenbaum et al 1997,
Kamara et al 1998), suggesting that high fat diets may act as a model of chronic
stress (Tannenbaum et al 1997). Thus in rodents, high fat diets may influence HPA
activity, without increasing circulating glucocorticoid levels. Likewise, in human
studies, obesity, increased visceral fat mass and derangement of metabolic variables
such as insulin, glucose, and triglycerides, are associated with abnormal HPA axis
variability, with a low diurnal Cortisol variation, and normal or low peak Cortisol
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levels (Rosmond et al 1998, Bjorntorp et al 1999, Rask et al 2001), although there is
evidence for HPA axis activation (Marin et al 1992, Pasquali et al 2002).
The metabolism of glucocorticoids by the isoenzymes of 11 P-HSD is important in
modulating the access of glucocorticoids to the glucocorticoid receptors GR and MR,
thereby determining local glucocorticoid effects (Seckl & Walker 2001).
Reactivation of corticosterone or Cortisol from their inactive metabolites by 11 p-
HSD 1 is predicted to increase tissue exposure to active glucocorticoid. Previous
studies in rodent models and in humans have demonstrated that obesity is associated
with altered 1 lp-HSD 1 activity, which is increased in adipose tissue (Livingstone et
al 2000a, Rask et al 2001, Paulmyer-Lacroix et al 2002, Rask et al 2002), but
decreased in liver (Livingstone et al 2000a, Rask et al 2001, Rask et al 2002).
Furthermore, there is evidence that altered 1 lp-HSD 1 activity may play a key role in
the pathogenesis of visceral obesity and the metabolic syndrome. Transgenic mice
over-expressing 11 p-HSD 1 specifically in adipose tissue develop visceral obesity
and features of the metabolic syndrome, without an increase in circulating
corticosterone levels (Masuzaki et al 2001). In contrast, mice homozygous for a
targeted disruption of the 11 P-HSD 1 gene exhibit attenuated gluconeogenic
responses to stress, resist hyperglycaemia and the development of visceral obesity on
exposure to a high fat diet and have improved hepatic insulin sensitivity and glucose
tolerance (Kotelevtsev et al 1997, Morton et al 2001).
In this study, exposure to a high fat diet for 3 weeks was accompanied by a down-
regulation of 11 P-HSD 1 activity in liver and adipose tissue. Although no difference
in 11 P-HSD 1 activity was evident at 24 hours, there was a clear trend for a down-
regulation in activity in subcutaneous fat at 72 hours. In addition, there was an acute
increase in the activity of hepatic 5p-reductase in HF animals at 24 hours, which was
maintained at 3 weeks. This combination of decreased hepatic 11 P-HSD 1 and
increased hepatic 5P-reductase activity is predicted to reduce local glucocorticoid
concentrations and is in agreement with findings in humans and in obese Zucker rats
(Livingstone et al 2000a, Rask et al 2001, Rask et al 2002). The resultant increase in
the glucocorticoid metabolic clearance rate (MCR) may however, result in increased
forward drive to the HPA axis to compensate for this, and to HPA axis activation.
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Thus, short-term exposure to a high fat diet results in changes in glucocorticoid
metabolism, before the development of obesity, which may act acutely to protect the
animal from the metabolic consequences of a high fat diet.
Although in the Zucker rat, obesity is associated with permanent down regulation of
hepatic 11 P-HSD 1, in this model, we observed no difference in hepatic lip-HSD 1
activity or mRNA levels after 20 weeks and 5P-reductase activity was normalised.
Additionally, in the longer term, the suppression of lip-HSD 1 activity was no
longer evident in adipose tissue. This failure to maintain suppression of adipose
11 p-HSD 1 following long-term exposure to a high fat diet may be important in the
pathogenesis of the metabolic complications of high fat feeding. Indeed, it is possible
that susceptibility to visceral obesity and its metabolic consequences may in part, be
determined by the ability to down-regulate adipose 11 p-HSD 1.
In transgenic mice, overexpression of 11 P-HSD 1 in visceral fat resulted not only in
increased adipose tissue concentrations of corticosterone, but also in increased levels
of corticosterone and free fatty acids in the hepatic portal vein (Masuzaki et al 2001).
Such an increase in the delivery of glucocorticoids and free fatty acids to the liver
may further contribute to hepatic insulin resistance. In our model, normalisation of
adipose 11 P-HSD 1 activity, together with increased fat mass may have similar
consequences. This effect is likely to be further compounded by the normalisation of
hepatic 11 P-HSD 1 and 5P-reductase activities, with a consequent increase in local
hepatic glucocorticoid concentration.
The mechanisms by which these enzymes are regulated remain unclear, but
candidates include resistance to insulin-mediated regulation, and secondary effects of
adipose products. Factors influencing lip-HSD 1 include glucocorticoids, TNFa,
thyroid hormones, sex steroids, GH, IGF-1, insulin and cytokines (Seckl & Walker
2001). Chronic stress or elevated glucocorticoid levels are associated with reduced
lip-HSD 1 activity (Jamieson et al 1999a). In addition, both PPARa and PPARy
agonists attenuate 11 P-HSD 1 activity (Hermanowski-Vosatka et al 2000, Berger et
al 2001). Treatment of ob/ob mice (which have reduced 11 P-HSD 1 activity in liver),
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with leptin increased hepatic 1 tp-HSD 1 mRNA and activity, in addition to reducing
body weight, plasma glucose and corticosterone (Liu et al 2003). Furthermore, leptin
increased lip-HSD 1 mRNA and activity in isolated hepatocytes, an effect which
appeared to be mediated via the leptin receptor (Liu et al 2003).
Although we found alterations in 11 P-HSD 1 activity in liver, omental and
subcutaneous fat after 3 weeks of high fat feeding, there were no differences in 11P-
FISD 1 mRNA in liver and omental fat. Studies in human adipocytes and in a
hepatoma cell line have shown down-regulatory effects of CRH and ACTH
(Friedberg et al 2003) and IGF-1 (Voice et al 1996) on lip-HSD 1 activity, without
any change in mRNA levels, suggesting that some effects on 11P-HSD 1 are exerted
post-transcriptionally. The reason for the discrepancy between enzyme activity and
mRNA levels of hepatic 5p-reductase is also unknown. The 5p-reductase enzyme
which has been purified from human liver shares approximately 75% homology with
that of the rat (Charbonneau & The 2001) and catalyses the transformation of 4-
androstenedione, testosterone, progesterone and 17a-hydroxyprogesterone in
addition to glucocorticoids and mineralocorticoids, which appear to be poorer
substrates (Charbonneau & The 2001). Despite the apparent poor affinity of this
enzyme for glucocorticoids, there is a higher abundance of 5P-reduced than 5a-
reduced glucocorticoid metabolites and it is possible that there is an as yet
undiscovered second 5P-reductase gene. Alternatively, the RNA may be rapidly
degraded; indeed the enzyme possesses a sequence motif (ATTTA) within the 3'
untranslated region, which is known to be associated with instability and rapid
degradation ofRNA (Shaw & Kamen 1986).
In this study we have demonstrated that changes in lip-HSD 1 and 5p-reductase
activities are an early change accompanying high fat feeding in rodents, and are seen
before the development of obesity. The changes in lip-HSD 1 appear to be
independent of insulin resistance, as they are not maintained in the long term, despite
a marked decline in insulin sensitivity. Indeed, these findings support a number of
other studies suggesting that changes in 11 p-HSD 1 are not due to hyperinsulinaemia
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or insulin resistance alone; studies using metformin and PPARy agonists have shown
that insulin sensitisation alone is insufficient to normalise the changes in 1 lp-HSD 1
enzyme activity in the obese Zucker rat (Livingstone et al 2000b), although high
dose PPARy agonists can attenuate adipose tissue lip-HSD 1 activity in db/db mice
(Berger et al 2001). Furthermore, in another rodent model, in which antenatal
dexamethasone treatment is associated with the development of insulin resistance in
adulthood, no changes are seen in hepatic 1 lp-HSD 1 mRNA (Nyirenda et al 1998)
and in a recent case-control study of lean men with hyperglycaemia and insulin
resistance, no changes were found in adipose tissue lip-HSD 1 (Andrews et al
2002).
In the obese Zucker rat, adrenalectomy reversed the tissue-specific alterations in
lip-HSD 1 (Livingstone et al 2000b), however adrenalectomy also normalises many
of the other features of the phenotype including obesity, insulin resistance and
hyperinsulinaemia. In lean Zucker rats, adrenalectomy had no effect on lip-HSD 1
activity in liver, but increased activity in adipose tissue (Livingstone et al 2000b); it
is therefore unlikely that the hypercorticosteronaemia alone is responsible for the
alterations in lip-HSD 1 observed in the obese Zucker rat. In our study, acute
changes in glucocorticoid metabolising enzymes were noted in the absence of
increased plasma corticosterone levels, suggesting that circulating glucocorticoid
levels may not play a major role in the regulation of these enzymes in animals on a
high fat diet.
Hepatic and omental fat GR mRNA levels were unchanged with high fat feeding in
both the short- and long-term experiments. One previous study has reported
decreased hypothalamic GR after one week on a high fat diet, although this
difference was not maintained after 9 or 12 weeks (Tannenbaum et al 1997). No
changes were noted in GR numbers in the hippocampus, frontal cortex or pituitary
(Tannenbaum et al 1997). In the obese Zucker rat, previous studies have reported
normal or reduced hepatic GR number and affinity (Shargill et al 1987, White &
Martin 1990, Langley & York 1992) and reduced MR but normal GR in the
hippocampus (Mattsson et al 2003). In contrast, in the dexamethasone-programmed
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rat, another rodent model associated with HPA axis activation (Levitt et al 1996) and
insulin resistance (Nyirenda et al 1998), although without the development of
obesity, GR is again altered in a tissue-specific manner; but in this model is
permanently upregulated in liver and visceral fat (Nyirenda et al 1998, Cleasby et al
2003a, Cleasby et al 2003b), and reduced in the hippocampus and certain muscle
types (Levitt et al 1996, Welberg et al 2001, Cleasby et al 2003a). In transgenic mice
overexpressing 11 P-HSD 1 in visceral fat, no alterations were found in GR mRNA in
mesenteric or subcutaneous fat (Masuzaki et al 2001).
The lack of any effect on GR mRNA expression of high fat feeding in Wistar rats
and in the adipose 11P-HSD 1 overexpressing mice, together with the different and
tissue-specific alterations observed in the obese Zucker and dexamethasone-
programmed rats, suggests that the changes in GR are unlikely to be mediated by
insulin resistance. Further evidence for this comes from recent studies in the
dexamethasone-programmed rat, showing that manipulation of circulating
corticosterone and insulin sensitisation are insufficient to normalise the programmed
changes in peripheral GR, suggesting that they are not secondary to the metabolic
derangement, but may be a primary mechanism underlying the metabolic
dysregulation in this model (Cleasby et al 2003b). However, it is possible that the
long term changes in HPA axis activity noted in this model of high fat feeding are
mediated by changes in GR or MR in central feedback sites, which we have not
explored in this study.
In conclusion, high fat feeding in Wistar rats leads to obesity and insulin resistance.
Short-term exposure to a high fat diet induces alterations in glucocorticoid
metabolism, with decreased 11 P-HSD 1 activity in liver and fat depots, and increased
hepatic 5P-reductase activity, in the absence of hyperinsulinaemia,
hypercorticosteronaemia or changes in GR. These alterations are not however,
maintained in the longer term, despite the development of obesity and insulin
resistance. This study therefore demonstrates that high fat feeding in Wistar rats is
not associated with the same changes in glucocorticoid metabolism as are seen in
genetic models of obesity, but does providing further support for previous studies
which have suggested that the alterations in glucocorticoid metabolism in models of
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obesity are not mediated by insulin resistance, hyperinsulinaemia or
hypercorticosteronaemia (Livingstone et al 2000b).
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Chapter Six - The effects of obesity in the dexamethasone
programmed rat
6.1 Introduction
The development of obesity appears to be an important factor modifying the risk of
later disease associated with low birth weight. Those individuals with the lowest
birth weight but highest current weight have the highest total body fat (Gale et al
2001) and are at increased risk of developing insulin resistance, type 2 diabetes and
high blood pressure (Phillips et al 1994, Lithell et al 1996, Leon et al 1998, Eriksson
et al 2002, Eriksson et al 2003). In human studies, prenatal famine exposure is linked
to decreased glucose tolerance in adulthood, particularly in those who become obese
(Ravelli et al 1998) and in the Leningrad siege study, a positive association between
obesity and blood pressure was found, with a relationship that was strongest in those
exposed to malnutrition in utero (Stanner et al 1997, Stanner & Yudkin 2001).
The importance of obesity as an amplifier of programming effects has been explored
in animal models in which antenatal nutritional manipulations have resulted in
offspring of low birth weight and postnatal growth failure. Rats exposed to maternal
undernutrition throughout gestation and maintained on a hypercaloric diet from
weaning developed hyperphagia, profound obesity, hyperglycaemia,
hyperinsulinaemia, hyperleptinaemia and hypertension (Vickers et al 2000, Vickers
et al 2001b).
We have explored the effects of obesity on the phenotype of the dexamethasone-
programmed rat, using the model of high fat feeding developed in chapter five.
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6.2 Methods
Male F1 pups bred in the programming experiment described in chapter four were
used. High fat and control diets were used as described in chapter five (Section 2.20).
At three weeks of age, 19 F1 dex pups were weaned onto the high fat diet (DHF),
and 15 onto the control diet (DC). Fourteen F1 veh animals were weaned onto high
fat (VHF) and 14 onto control (VC) diets. Animals were used from all F1 litters (n=8
litters per group), and in all cases experimental cohorts included males selected
randomly from as many litters as possible. Animals were caged in groups of four or
five, with ad libitum access to the respective diets. All were weighed at weaning and
2-weekly thereafter.
Glucose tolerance tests were conducted at 15 weeks and 6 months on 8-10 animals
from each group. Plasma glucose was determined by the enzymatic (hexokinase)
method, and plasma insulin by ELISA.
At 6 months, rats from each group were weighed, culled and tissues dissected,
weighed and snap-frozen on dry ice (n=7-9 per group).
6.3 Results
6.3.1 Body weights
As described in chapter four, F1 dex animals were significantly lighter than F1 veh
animals at birth (Table 4.1). F1 dex males remained lighter at weaning (Figure 6.1).
F1 dex animals in both HF and C groups achieved catch-up growth by 7 weeks of
age (Figure 6.1).
Analysis of variance revealed that both DHF and VHF rats were significantly heavier
than controls of the same prenatal treatment group by 5 weeks of age and thereafter
remained heavier throughout the time of follow-up (Figure 6.1).
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Figure 6.1 Body weights from weaning in HF and C groups.
Data were analysed by ANOVA * denotes p<0.05 between HF and C
f denotes p<0.05 between dex and veh in both HF and C groups, n=14







Animals on the high fat diet were hyperinsulinaemic by 15 weeks of age, although no
differences were noted in glucose levels between groups. The high fat diet was
associated with higher insulin levels at 30 minutes in both DHF and VHF animals
(Figure 6.2).
At 6 months, no differences were noted in glucose levels between groups (Figure
6.3). Against a background ofmaternal veh, the high fat diet increased insulin levels
at 120 minutes (VHF animals), however against a background of maternal dex, the
high fat diet increased plasma insulin at 30 and 120 minutes (DHF animals) (Figure
6.3).
6.3.3 Organ weights
At 6 months, both VHF and DHF animals had increased retroperitoneal fat pad
weight, and a trend for an increase in hepatic weight (Figure 6.4), however there
were no differences between Dex and Veh animals in the same dietary group.
6.3.4 Hepatic triglyceride content1
At 6 months both VHF and DHF animals had increased hepatic triglyceride levels
(Figure 6.5). Against a background ofmaternal veh, the high fat diet increased liver
triglyceride content, however against a background of maternal dex the high fat diet
increased liver triglyceride content to a greater extent, such that hepatic triglyceride
content was higher in DHF than VHF animals.
1 Measurement of hepatic triglyceride content was carried out by Dr Peter Raubenheimer,
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Figure 6.2 Glucose and insulin at 15 weeks.
Glucose (panel A) and insulin (panel B) following a glucose load (n=10 per
group). 2-way ANOVA revealed an effect of the high fat diet to increase
insulin levels in both dex and veh animals (*p<0.05). Post hoc analysis















































Figure 6.3 Glucose tolerance testing at 6 months.
Glucose (panel A) and insulin (panel B) at 6 months of age (n= 10 VHF, 9 DHF, 9
VC and 8 DC).
2-way ANOVA revealed an effect of the high fat diet to increase insulin levels in
both dex and veh animals (*p<0.05). Post hoc analysis revealed an additional







Figure 6.4 Body weight (panel A), liver weight (panel B) and retroperitoneal fat
weight (panel C) at 6 months.
Data were analysed by ANOVA. There was an effect of the high fat diet to
increase body weight and retroperitoneal fat weight in both dex and veh animals
(p<0.05, n= 8 VHF, 9 DHF, 7 VC and 8 DC), but no significant effect of prenatal















VHF DHF VC DC
Figure 6.5 Hepatic triglyceride content at 6 months.
Analysis by ANOVA revealed an effect of diet to increase hepatic
triglyceride levels in DHF and VHF animals (* p<0.05, n= 8 VHF, 8
DHF, 6 VC and 8 DC). Post hoc testing revealed an additional effect of
prenatal dexamethasone treatment to further increase hepatic triglyceride
content in DHF animals (| p<0.05).
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6.4 Discussion
These results demonstrate that high fat feeding in the dexamethasone-programmed
rat is associated with some amplification of the phenotype. In the group of animals,
described in this chapter and in chapter four, antenatal dexamethasone treatment was
associated with low birth weight, but not with elevated hepatic PEPCK or with
glucose intolerance in dex animals on the control diet, consistent with a mild
programming phenotype. Postnatal exposure to a high fat diet was associated with
obesity and insulin resistance in both dex and veh animals. This effect appeared to be
subtly amplified in the dexamethasone programmed group, with hyperinsulinaemia
and increased liver fat accumulation, but no increase in obesity, suggesting a specific
programming effect on the liver.
In animal models, fetal undernutrition secondary to the use of a low protein or a
calorie restricted diet during gestation is associated with reduced birth weight and
later metabolic abnormalities (Langley et al 1994, Langley & Jackson 1994, Hales et
al 1996, Woodall et al 1996a, Woodall et al 1996b, Garofano et al 1999, Vickers et al
2000, Vickers et al 2001b). In low protein rat models, in utero exposure to a low
protein diet appears to be associated with insulin resistance and/ or insulin deficiency
(Hales et al 1996) and subsequent high fat feeding leads to impaired insulin secretion
and impaired glucose tolerance (Holness 1996, Wilson & Hughes 1997). In addition
to the metabolic sequelae, maternal calorie restriction in rats is associated with an
increased risk of obesity in offspring. Calorie restriction during the first two weeks of
gestation was associated with normal offspring birth weight and normal initial
postnatal growth, however by 53 days, female offspring had increased fat pad
weights although no difference in total body weight compared with controls (Anguita
et al 1993). In contrast, male offspring of calorie restricted dams showed lower total
body weight and lower fat pad weight by 53 days (Anguita et al 1993). In more
recent studies in which calorie restriction throughout gestation was associated with a
marked reduction in birth weight and the subsequent development of higher blood
pressure and hyperinsulinaemia (Vickers et al 2000, Vickers et al 2001b),
malnourished pups of both sexes which were cross-fostered onto control mothers and
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weaned onto normal diets did not demonstrate catch-up growth, but did show
hyperphagia, more sedentary behaviour and increased fat pad weight relative to body
weight (Vickers et al 2000, Vickers et al 2003). Exposure of these offspring to a high
fat diet (30% fat) after weaning amplified the metabolic and cardiovascular
abnormalities; animals became obese, had higher plasma insulin and leptin levels and
higher blood pressure (Vickers et al 2000). The authors suggest that fetal
undernutrition induces hyperleptinaemia, hyperinsulinism and insulin and leptin
resistance, which may underpin the hyperphagia, obesity and hypertension in this
model (Vickers et al 2000). They also speculate that there may be dysregulation of
the adipoinsular axis, with impaired leptin suppression of insulin secretion resulting
in chronic hyperinsulinaemia, increased adipogenesis and further elevations in
plasma leptin (Seufert et al 1999, Vickers et al 2001b).
In the original model of dexamethasone programming in the rat, low birth weight
was associated with the subsequent development of glucose intolerance, with fasting
and postglucose hyperglycaemia and hyperinsulinaemia (Nyirenda et al 1998).
Enhanced hepatic glucose output as a result of programmed hepatic PEPCK
overexpression may explain the observed glucose intolerance, indeed as discussed in
chapter three, there is no evidence for altered peripheral glucose disposal uptake in
this model (Cleasby et al 2003a). In one study, in which dexamethasone-exposed
animals had reduced birth weight and postglucose hyperglycaemia, but which did not
demonstrate complete catch-up growth, programmed animals did not show any
changes in plasma leptin, and had smaller fat pads than controls at 7 months of age
(Cleasby et al 2003a).
In the cohort of F1 animals described in this chapter, the programming effect appears
to have been very mild; birth weight was reduced in the dex treated animals, but
there was no change in hepatic PEPCK. Consistent with this, there was no evidence
of glucose intolerance in dex animals on the control diet, at least during a glucose
tolerance test. However, there was evidence for a subtle amplification of the
programming effect in the dex animals on a high fat diet. Although both dex and veh
animals on the high fat diet showed no evidence of hyperglycaemia, the dex animals
on a high fat diet showed a greater increase in plasma insulin during the glucose
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tolerance test when compared with their littermates on the control diet, than the veh
animals, suggesting increased insulin resistance in the DHF group. This is despite no
evidence that the dex HF animals were more obese that the veh HF group, as
assessed by body weight and fat pad weight.
In agreement with previous reports (Ye et al 2003), the high fat diet induced an
increase in hepatic triglyceride content. In human subjects, fatty liver is associated
with obesity and diabetes (Marceau et al 1999, Marchesini et al 2001) and is strongly
related to insulin resistance (Marchesini et al 2001, Sanyal et al 2001, Pagano et al
2002). The underlying mechanisms are unclear, but may include increased free fatty
acid delivery to the liver from visceral fat stores. In obese individuals there may be a
finite amount of triglyceride storage in adipose depots, resulting in the diversion and
deposition of triglycerides in other tissues including the liver (Garg & Misra 2002).
Fatty acids increase hepatic gluconeogenesis, inhibit insulin suppression of
glycogenolysis and may cause hepatic insulin resistance (Boden et al 2002, Lam et al
2003). Furthermore, in states of energy excess, fatty acid metabolism may be
diverted into esterification, increasing hepatic triglyceride content (Ruderman et al
1999, Lam et al 2003), and further increasing hepatic insulin resistance (Lam et al
2003).
In this study, DHF animals were more hyperinsulinaemic and had greater hepatic
triglyceride content than VHF animals, although there was no increase in obesity.
This increase in hepatic triglyceride content may be mediated by glucocorticoids.
Rats exposed to excess glucocorticoid in utero have increased hepatic GR (Nyirenda
et al 1998) in the presence of normal or increased circulating corticosterone levels
(Levitt et al 1996, Nyirenda et al 1998) and no alteration in hepatic lip-HSD 1
(Nyirenda et al 1998). The increase in hepatic GR is likely to be associated with an
increase in local glucocorticoid action, increasing hepatic insulin resistance.
Additionally, programmed animals have increased adipose GR and decreased
adipose tissue fatty acid uptake, consistent with insulin resistance in this tissue
(Cleasby et al 2003a). Glucocorticoids increase hormone sensitive lipase synthesis;
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therefore increased glucocorticoid action and insulin resistance in visceral adipose
tissue may increase lipolysis, potentially increasing free fatty acid flux into the liver.
In addition to its role in gluconeogenesis, PEPCK is a rate-limiting enzyme in
glyceroneogenesis in both liver and adipose tissue. Glyceroneogenesis, the
conversion of pyruvate and amino acids to 3-glycerol phosphate for the synthesis of
glyceride-glycerol (Reshef et al 2003), is an abbreviated form of gluconeogenesis
and is thought to have a role in the re-esterification of fatty acids in adipose tissue
and liver, reducing fatty acid release from adipose tissue and enhancing release from
the liver in the form of triglyceride (Reshef et al 1970, Martin-Sanz et al 1990,
Reshef et al 2003). However, the potential importance of glyceroneogenesis and the
role of PEPCK in the control of fatty acid recycling in adipose tissue and liver in
disease remain to be determined. Glucocorticoids stimulate PEPCK gene
transcription in liver, but repress it in adipose tissue (Sasaki et al 1984, Meisner et al
1985, Nechushtan et al 1987); adrenalectomy enhances glyceroneogenesis and
diminishes fatty acid release from adipose tissue in vitro (Reshef et al 1969), whereas
the addition of glucocorticoids to cultured hepatocytes increased the synthesis of
triglycerides and stimulated the release of very low density lipoproteins (Martin-Sanz
et al 1990). Although in this experiment we did not demonstrate elevated hepatic
PEPCK activity in the group of dex animals in which it was measured at weaning; it
is an intriguing possibility that in the programmed animal a glucocorticoid-mediated
increase in PEPCK expression in the liver might contribute to the increased hepatic
triglyceride storage. Conversely, a glucocorticoid-induced downregulation in PEPCK
expression in adipose tissue may suppress glyceroneogenesis in fat stores, resulting
in an increased flow of free fatty acids to the liver.
Thus, the amplification of the programming effect by obesity may be related to
glucocorticoid dependent changes in hepatic metabolism and insulin resistance,
which may be altered in the programmed animal. Although time has not permitted
further exploration of glucocorticoid signalling within these animals (as described in
chapter five), alterations in glucocorticoid metabolism in programmed animals may
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underpin the amplification of the programming effect by obesity and require further
exploration.
Could this be relevant in the human population? Epidemiological studies
demonstrate that low birth weight is a risk factor for the development of obesity
during childhood and adulthood (Ong et al 2000), which may modify the risk of later
disease (Phillips et al 1994, Lithell et al 1996, Leon et al 1998, Eriksson et al 1999,
Forsen et al 2000, Eriksson et al 2001, Law et al 2002) and postnatal nutrition is
likely to be important in mediating this (Lucas 1991, Singhal et al 2001, Singhal et al
2003). Low birth weight is associated with later insulin resistance and the metabolic
syndrome (Barker 1998), conditions which are associated with fatty liver disease
(Marceau et al 1999, Marchesini et al 2001). Thus, in humans, the combination of in
utero effects and later nutritional status may have important implications for adult
health. This animal model may provide important insights into how the postnatal
environment may amplify the metabolic and cardiovascular abnormalities associated
with low birth weight.
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Chapter Seven - Discussion
The aim of this thesis was to study the intergenerational effects of programming by
in utero exposure to excess glucocorticoid in the rat and to explore the influence of
parental in utero glucocorticoid exposure on offspring phenotype. We also describe
the development of a model of diet-induced obesity, which was subsequently applied
to the programming model to examine the amplification of the programming
phenotype by obesity. A summary is presented in figure 7.1.
7.1 The intergenerational effects of dexamethasone programming
We have explored intergenerational effects in an animal model of fetal programming,
the dexamethasone-programmed rat. In this model, administration of dexamethasone
to female Wistar rats during the last week of a three-week pregnancy results in
offspring of low birth weight, with elevated hepatic PEPCK activity, which
subsequently develop glucose intolerance and hypertension in adulthood
(Benediktsson et al 1993, Nyirenda et al 1998). Using this model we have been able
to demonstrate a consistent effect in a second (F2) generation (F2 dex and F2 veh).
Without any further manipulation, second generation offspring of dexamethasone
treated rats are also of low birth weight, with elevated hepatic PEPCK activity. The
programming effect appears to be stronger in the F2 generation than in F1 animals,
and in male offspring. Male F2 dex offspring are glucose intolerant by four months
of age and have higher blood pressures in adulthood. Female F2 dex offspring have
some evidence for insulin resistance in adulthood, but do not demonstrate abnormal
blood pressure. No intergenerational effects on birth weight, hepatic PEPCK activity,
or glucose tolerance were detectable in a third generation.
It has been proposed that the increased expression of PEPCK in this model may be
secondary to increased hepatic GR expression in the presence of normal circulating
concentrations of corticosterone (Nyirenda et al 1998). We found no differences in
circulating corticosterone levels in males or females in any of the generations
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studied, but due to time constraints we were unable to explore GR expression.
However, given the intergenerational effects we have described on hepatic PEPCK
and glucose tolerance, future studies in this model should address GR expression in
the second and third generations.
There were a number of sex-specific effects noted in this study. The postnatal growth
ofmales and females in the F1 cohort described in chapter three differed, with males,
but not females, achieving catch up growth. However, the intergenerational effects
on glucose tolerance and blood pressure in the F2 animals appeared stronger in
males. A number of sex-specific effects have been described in animal models of
fetal programming (Hales et al 1996, Dean & Matthews 1999, Kind et al 1999,
Lingas et al 1999, Dean et al 2001, Lingas & Matthews 2001, Liu et al 2001, Owen
& Matthews 2003) and human studies have revealed some sex differences in the
long-term disease risk associated with low birth weight (Forsen et al 2000, Walker et
al 2002), or exposure to famine prenatally (Ravelli et al 1999). Recent studies have
shown different patterns of development of GR and MR in male and female guinea
pig brains, which may underlie the sex-specific effects of prenatal glucocorticoid
exposure on HPA regulation in this animal (Owen & Matthews 2003). We have not
explored in detail the mechanisms of the sex-specific effects in this model, however
the differential sensitivity of males and females to programming phenomenon may
be due to the influence of sex steroids, sex chromosome effects, sex-specific patterns
of development, parental imprinting or differences in maternal care. Indeed, although
not apparent in our model, stronger programming effects in females could further
amplify a matrilineal pattern of intergenerational inheritance.
In terms ofmechanisms, studies demonstrating intergenerational effects of maternal
dietary manipulations on birth weight, pancreatic development and glucose
homeostasis in rats (Laychock et al 1995, Vadlamudi et al 1995, Martin et al 2000,
Srinivasan et al 2003) suggest that in utero exposure to an adverse environment
might lead to a perpetuation of programming effects in subsequent generations.
Antenatal dexamethasone exposure may produce permanent alterations in maternal
physiology, which might impact on a developing fetus and lead to a perpetuation of
programming effects in subsequent generations. Human studies have suggested that
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poor maternal intrauterine growth and a lack of catch up growth may have effects on
uterine size, which could have an impact upon fetal growth. In our studies, the F1
dex and veh females described in chapter four showed no difference in body weight
at the time of conception, suggesting that maternal size was not a major determinant
of offspring size in this model. There are, however, a number of other maternal
factors that may result in the intergenerational effects described in this thesis, and
which remain to be explored. Although there were no differences in basal
corticosterone levels in F1 or F2 females, we did not exclude alterations in peak
levels, or changes across the full diurnal rhythm, nor did we measure glucocorticoid
levels during pregnancy. Clearly, given the programming effects of glucocorticoid
exposure in utero in the F1 generation, maternal hypercorticosteronaemia might play
a key role in the potentiation of such effects in subsequent generations. Similarly,
alterations in maternal insulin levels or blood pressure during pregnancy were not
assessed and future studies will address these potential mechanisms in this model.
However, as we have shown, maternal factors are not sufficient to explain all of the
intergenerational effects described and both maternal and paternal dexamethasone
exposure has an effect on the phenotype of the F2 offspring. Paternal prenatal
dexamethasone exposure produced a greater reduction in birth weight in offspring of
control mothers than of dexamethasone-exposed mothers, emphasising an important
effect of the father on the intergenerational transmission of programming effects. The
offspring of dex-programmed fathers also had increased offspring PEPCK expression
irrespective of maternal dex exposure, although, unlike birth weight, maternal dex
programming appeared a more potent determinant of offspring PEPCK expression.
Further phenotyping of the F2 offspring of crosses between dex and vehicle animals
including glucose tolerance is awaited. We suggest that these intergenerational
effects, which are transmissible from both parents, may be secondary to epigenetic
effects on the genome. Indeed, as discussed in chapter four, recent studies have
suggested that environmental influences such as glucocorticoids may have epigenetic
effects on the offspring, and that some epigenetic modifications may be transmitted
from either parent, or both.
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Glucocorticoid programming
Treatment of pregnant Wistar rats with dexamethasone (dex; lOOpg/kg), or
vehicle (veh) days 15-21.
F1 dex and F1 veh offspring






















Figure 7.1 Summary of results
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7.2 The amplification ofprogramming by obesity
In chapter four we describe the development of a model of diet-induced obesity in
male Wistar rats, in which we examined changes in glucocorticoid metabolism.
Exposure ofWistar rats to a high fat diet is not associated with the same changes in
glucocorticoid signalling and metabolism that have been described in other animal
models of obesity such as the obese Zucker rat, in which reactivation of
corticosterone by 11P-HSD 1 is impaired in liver, but enhanced in omental adipose
tissue. Similar alterations in glucocorticoid metabolism by 11 P-HSD 1 have been
demonstrated in human obesity. In this study we have shown that in the Wistar rat,
short-term exposure to a high fat diet induces alterations in glucocorticoid
metabolism, with decreased 11 P-HSD 1 activity in liver and fat depots, and increased
hepatic 5p~reductase activity, in the absence of obesity, hyperinsulinaemia,
hypercorticosteronaemia or changes in hepatic or omental adipose GR. These
alterations are not however, maintained in the longer term, despite the development
of obesity and insulin resistance. We suggest that the early down regulation of 11P-
HSD 1 in this model, together with the upregulation of hepatic 5P-reductase activity
results in increased glucocorticoid clearance and may reflect a protective mechanism
against the metabolic consequences of a high fat diet. This hypothesis is supported
by studies demonstrating that mice with a targeted disruption of the 11 P-HSD 1 gene
are protected from some of the metabolic consequences of obesity (Kotelevtsev et al
1997). The mechanisms underlying this remain to be determined, however these data
are in agreement with previous studies that have demonstrated that alterations in
11 P-HSD 1 and GR do not appear to be dependent on hyperinsulinaemia or
hypercorticosteronaemia (Livingstone et al 2000b). It is possible that very long term
high fat feeding in this model might be associated with further alterations in 11 p-
HSD 1 and GR; a further study is already in progress to examine the effects of very
long term (40 weeks) high fat feeding in Wistar rats on glucocorticoid metabolism.
In order to explore the effects of obesity in this programming model, we applied this
model of dietary obesity to F1 dex and F1 veh males. In both F1 dex and F1 veh
males, the high fat diet induced weight gain, increased retroperitoneal fat pad weight
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and caused hyperinsulinaemia and increased liver triglyceride content. However, by
6 months of age there were no differences between dex and veh animals in weight
gain or retroperitoneal fat pad weight. Thus, antenatal dexamethasone exposure does
not appear to confer increased sensitivity to obesity induced by high fat feeding.
However, F1 dex animals did show greater hyperinsulinaemia and increased hepatic
triglyceride accumulation in response to the high fat diet. Again, the mechanisms
underlying this remain to be determined, but the increased hepatic lipid accumulation
may reflect decreased hepatic insulin sensitivity. Further studies are required to
determine whether alterations in glucocorticoid signalling are important in the
pathogenesis of hepatic triglyceride accumulation in programmed animals.
7.3 Implications for human populations
Epidemiological studies have demonstrated that there is an important relationship
between early life experience and subsequent adult disease, and additionally, results
from human and animal studies suggest that 'programmed' effects may be
transmitted through subsequent generations. The thrifty phenotype hypothesis
includes the concept that 'the poorly nourished mother essentially gives the fetus a
forecast of the nutritional environment into which it will be born' (Hales & Barker
2001). Physiological adaptations prepare the fetus for the same extrauterine
conditions, optimising survival at least until after reproduction, under conditions of
stress or deprivation. Such non-genomic influences on fetal growth and development
acting across a number of generations would help to ensure continued population
survival. However, these intergenerational effects of fetal programming would only
be advantageous to population survival when environmental conditions remain
consistent over several generations. Any rapid change in the environment puts the
'programmed' offspring at risk of hypertension and glucose intolerance. This is
clearly seen in developing countries where peoples leading 'traditional' lifestyles
have a low prevalence of type 2 diabetes (King & Rewers 1993). The prevalence of
diabetes, hypertension and cardiovascular disease in such populations increases
rapidly with urbanisation or migration to other countries, associated with changes in
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diet, exercise and the resultant increase in obesity (Cruickshank et al 2001, Fall
2001).
Transgenerational programming effects may therefore lead to the inheritance of a
predisposition for low birth weight and cardiovascular risk and have important
consequences for cardiovascular risk across a number of generations for populations
in both developed and developing societies. However, attempts to investigate the
underlying mechanisms of intergenerational effects on birth weight and
cardiovascular risk factors using epidemiological studies in human populations are
limited by a number of factors, including genetic differences between populations,
postnatal environment, lifestyle and diet. Animal models of intergenerational
programming in which environmental and genetic variations are minimised are
therefore valuable tools in which to dissect and validate potential mechanisms. This
model of intergenerational programming provides an exciting opportunity to explore
the role of programmed maternal factors and epigenetic influences in the
intergenerational transmission of programming effects on birth weight and later
disease risk.
Obesity is linked with a number of health consequences including type 2 diabetes
and cardiovascular disease and additionally, alterations in glucocorticoid secretion
and metabolism have been shown in human obesity and in animal models. In the
model of fetal programming used in these experiments, alterations in glucocorticoid
signalling appear to be important mediators of the long-term consequences of
programming. We have shown that programmed animals appear to be more
susceptible to the metabolic consequences of a high fat diet, in the absence of
increased obesity, which may be related to glucocorticoid-dependent changes in
hepatic metabolism and insulin resistance. These results suggest that the combination
of obesity and adverse antenatal environment may interact to alter hepatic insulin
sensitivity in this model.
Epidemiological studies in humans suggest that obesity is an important modifier of
the risks associated with low birth weight and thus, in humans as well as animal
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models, the combination of in utero effects and later nutritional status may have
important implications for adult health. This animal model will allow us to further
explore how obesity may interact with programming effects to amplify the metabolic
and cardiovascular abnormalities associated with low birth weight.
To conclude, epidemiological studies and animal models suggest that
intergenerational effects of fetal programming could be associated with major public
health implications for populations in both developed and developing worlds. There
may be unforeseen long-term and intergenerational effects of interventions that
impact on early human development. Indeed, we have shown that antenatal
glucocorticoid exposure is associated with intergenerational effects on birth weight
and on cardiovascular risk factors in this animal model. Furthermore, postnatal
environmental factors such as diet may modify the risk of disease associated with
low birth weight. The animal models developed in this thesis will allow us to explore
further the mechanisms of intergenerational programming effects and the
consequences ofpostnatal nutrition and obesity.
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